

CONSOLIDATED FINANCIAL STATEMENTS,
SUPPLEMENTARY INFORMATION, UNIFORM
GUIDANCE REPORTS AND SCHEDULE

Mayo Clinic
Years Ended December 31, 2020 and 2019

Ernst & Young LLP



Mayo Clinic

Consolidated Financial Statements, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2020 and 2019

Contents

Independent auditor's report.....	1
Consolidated financial statements	
Consolidated statements of financial position	3
Consolidated statements of activities	4
Consolidated statements of cash flows	5
Notes to consolidated financial statements.....	6
Supplementary Information	
Financial Responsibility Supplemental Schedule required by the U.S. Department of Education	51
Schedule of Expenditures of Federal Awards	52
Schedule of Expenditures of Florida State Financial Assistance	91
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance	92
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	94
Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, <i>Rules of the Auditor General of the State of Florida</i>	96
Schedule of Findings and Questioned Costs	101



Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

Report of Independent Auditors

Board of Trustees
Mayo Clinic

We have audited the accompanying consolidated financial statements of Mayo Clinic (the “Clinic”), which comprise the consolidated statements of financial position as of December 31, 2020 and 2019, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion


In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Mayo Clinic at December 31, 2020 and 2019, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to February 19, 2021. The financial responsibility supplemental schedule required by the U.S. Department of Education and the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated February 19, 2021, on our consideration of Mayo Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Mayo Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Mayo Clinic's internal control over financial reporting and compliance.



February 19, 2021, except for the schedules
of expenditures of federal awards and
Florida state financial assistance, for
which the date is March 29, 2022



Consolidated Statements of Financial Position
December 31, 2020 and 2019 (In Millions)

	2020	2019
Assets		
Current assets:		
Cash and cash equivalents	\$ 72	\$ 48
Accounts receivable for medical services	1,756	2,020
Securities lending collateral	2	1
Other receivables	576	458
Other current assets	252	201
Total current assets	2,658	2,728
Investments	14,320	11,135
Investments under securities lending agreement	38	19
Other long-term assets	1,204	1,023
Property, plant and equipment, net	4,964	4,834
Total assets	\$ 23,184	\$ 19,739
Liabilities and net assets		
Current liabilities:		
Accounts payable	\$ 584	\$ 512
Accrued payroll	797	667
Accrued employee benefits	163	158
Deferred revenue	90	43
Long-term variable-rate debt	620	710
Mandatory tender debt	135	—
Securities lending payable	2	1
Other current liabilities	470	473
Total current liabilities	2,861	2,564
Long-term debt, net of current portion	3,097	2,647
Accrued pension and postretirement benefits, net of current portion	2,897	2,500
Other long-term liabilities	1,964	1,634
Total liabilities	10,819	9,345
Net assets:		
Without donor restrictions	8,016	6,679
With donor restrictions	4,349	3,715
Total net assets	12,365	10,394
Total liabilities and net assets	\$ 23,184	\$ 19,739

See notes to consolidated financial statements.



Consolidated Statements of Activities
Years Ended December 31, 2020 and 2019 (In Millions)

	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains and other support:						
Medical service revenue	\$ 11,501	\$ —	\$ 11,501	\$ 11,604	\$ —	\$ 11,604
Grants and contracts	569	—	569	568	—	568
Investment return allocated to current activities	238	32	270	221	26	247
Contributions available for current activities	91	258	349	60	211	271
Other	1,221	—	1,221	1,018	—	1,018
Net assets released from restrictions	246	(246)	—	270	(270)	—
Total revenue, gains and other support	13,866	44	13,910	13,741	(33)	13,708
Expenses:						
Salaries and benefits	8,064	—	8,064	7,670	—	7,670
Supplies and services	4,099	—	4,099	4,076	—	4,076
Depreciation and amortization	611	—	611	587	—	587
Facilities	276	—	276	290	—	290
Finance and investment	132	—	132	133	—	133
Total expenses	13,182	—	13,182	12,756	—	12,756
Income (loss) from current activities	684	44	728	985	(33)	952
Noncurrent and other items:						
Contributions not available for current activities, net	(21)	250	229	(22)	278	256
Unallocated investment return, net	1,144	340	1,484	711	255	966
Income tax expense	(40)	—	(40)	(24)	—	(24)
Benefit credit	62	—	62	134	—	134
Other	4	—	4	(4)	—	(4)
Total noncurrent and other items	1,149	590	1,739	795	533	1,328
Increase in net assets before other changes in net assets	1,833	634	2,467	1,780	500	2,280
Pension and other postretirement benefit adjustments	(496)	—	(496)	(1,038)	—	(1,038)
Increase in net assets	1,337	634	1,971	742	500	1,242
Net assets at beginning of year	6,679	3,715	10,394	5,937	3,215	9,152
Net assets at end of year	\$ 8,016	\$ 4,349	\$ 12,365	\$ 6,679	\$ 3,715	\$ 10,394

See notes to consolidated financial statements.



Consolidated Statements of Cash Flows
Years Ended December 31, 2020 and 2019 (In Millions)

	2020	2019
Cash flows from operating activities:		
Cash from medical services	\$ 10,904	\$ 10,681
Cash from external lab services	861	731
Cash from grants and contracts	555	522
Cash from benefactors	271	217
Cash from other activities	1,052	816
Cash for salaries and benefits	(7,827)	(7,648)
Cash for supplies, services, and facilities	(4,369)	(4,271)
Interest and dividends received	145	203
Interest paid	(115)	(117)
Income taxes paid	(6)	(34)
Net cash provided by operating activities	1,471	1,100
Cash flows from investing activities:		
Purchase of property, plant and equipment	(642)	(723)
Purchases of investments	(5,913)	(3,274)
Sales and maturities from investments	4,463	2,735
Investment in joint venture	(50)	—
Net cash used in investing activities	(2,142)	(1,262)
Cash flows from financing activities:		
Restricted gifts, bequests and other	214	252
Borrowing on long-term debt	630	—
Payment of long-term debt	(134)	(63)
Payment on leases	(15)	(8)
Medicare advance payments	915	—
Return of Medicare advance payments	(915)	—
Net cash provided by financing activities	695	181
Net increase in cash and cash equivalents	24	19
Cash and cash equivalents at beginning of year	48	29
Cash and cash equivalents at end of year	\$ 72	\$ 48

See notes to consolidated financial statements.

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota and Wisconsin affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

Certain reclassifications have been made to the 2019 consolidated financial statements to conform with classifications used in 2020. The reclassifications had no significant effect on total assets, total liabilities, total revenue or total change in net assets previously reported.

Use of estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standard:

Effective January 1, 2020, the Clinic adopted FASB Accounting Standards Update (ASU) No. 2018-13, *Fair Value Measurement (Topic 820)*. This ASU improves the effectiveness of the notes to financial statements through changes in the disclosure requirements for fair value measurement. The adoption of this ASU did not materially impact the consolidated financial statements.

New Accounting Standards Not Yet Adopted:

In August 2018, the FASB issued ASU No. 2018-14, *Compensation - Retirement Benefits - Defined Benefit Plans (Topic 715)*. This ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The ASU is effective January 1, 2021 and will be applied using a retrospective approach. Adoption of this ASU will not have a significant impact on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, *Intangibles - Goodwill and Other, Internal-Use Software (Subtopic 350-40), Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*. The primary effect of adopting this ASU will be capitalization of implementation costs incurred in hosting arrangements that are service contracts and subsequent amortization expense in the consolidated statements of activities. The ASU is effective

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

January 1, 2021 and will be applied using a prospective approach. The Clinic is currently assessing the impact of this ASU on its consolidated financial statements.

In September, 2020, the FASB issued ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958)*. This ASU requires presentation of contributed nonfinancial assets as a separate line in the consolidated statement of activities, apart from contributions of cash or other financial assets. The ASU is effective January 1, 2022 and will be applied on a retrospective basis. The Clinic is currently assessing the impact of this ASU on its consolidated financial statements.

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 5). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends) is included in the consolidated statements of activities.

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds), represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant and equipment: Property, plant and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. For the most part, the plan operates similar to a defined contribution plan.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions - Net assets subject to donor imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement.

Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$89 and \$96 in 2020 and 2019, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$540 and \$494 in 2020 and 2019, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of \$48 (\$27 allocated to current and \$21 allocated to noncurrent) and \$47 (\$25 allocated to current and \$22 allocated to noncurrent) were incurred in 2020 and 2019, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification. Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2020 through February 19, 2021, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are comprised of the following at December 31:

	2020	2019
Cash and cash equivalents	\$ 72	\$ 48
Accounts receivable	1,756	2,020
Promises to give	234	185
Grants receivable	134	114
Other receivables	208	159
Investments	8,878	6,997
Total financial assets available within one year	<u>\$ 11,282</u>	<u>\$ 9,523</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 and \$100 of available lines of credit for working capital at December 31, 2020 and 2019 (see Note 8 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 12 - Endowment, under the Clinic spending policy, \$224 from the endowments was available as of January 1, 2021 and \$207 from the endowments was available at January 1, 2020.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at

Note 3. Medical Service Revenue (Continued)

a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Note 3. Medical Service Revenue (Continued)

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2020 and 2019, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2020 and 2019 was not significant.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price were not significant in 2020 and 2019.

Patients who meet the Clinic's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts which are determined to qualify as charity care are not reported as revenue.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2020 and 2019 are as follows:

	Year Ended December 31, 2020			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 4,353	\$ 840	\$ 1,041	\$ 6,234
Clinic	2,885	649	727	4,261
Senior Care and Nursing Home	16	—	—	16
Other	50	1	—	51
Total patient care service revenue	7,304	1,490	1,768	10,562
External lab	939	—	—	939
Total medical service revenue	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 3,874	650	727	\$ 5,251
Services transferred over time	4,369	840	1,041	6,250
Total	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>
	Year Ended December 31, 2019			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 4,412	\$ 770	\$ 1,017	\$ 6,199
Clinic	3,273	652	679	4,604
Senior Care and Nursing Home	18	—	—	18
Other	51	—	—	51
Total patient care service revenue	7,754	1,422	1,696	10,872
External lab	732	—	—	732
Total medical service revenue	<u>\$ 8,486</u>	<u>\$ 1,422</u>	<u>\$ 1,696</u>	<u>\$ 11,604</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,056	\$ 652	\$ 679	\$ 5,387
Services transferred over time	4,430	770	1,017	6,217
Total	<u>\$ 8,486</u>	<u>\$ 1,422</u>	<u>\$ 1,696</u>	<u>\$ 11,604</u>

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology and other hospital related services in the Midwest region as clinic revenue in the amount of \$889 and \$1,110 for the years ended December 31, 2020 and

Note 3. Medical Service Revenue (Continued)

2019, respectively. Examples of revenue at time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2020	2019
Medicare	\$ 2,833	\$ 2,819
Medicaid	373	379
Contract	6,779	6,937
Other, including self-pay	1,516	1,469
Total	<u>\$ 11,501</u>	<u>\$ 11,604</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

Financing component:

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Note 4. Fair Value Measurements (Continued)

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2020 and 2019.

The following tables present the financial instruments carried at fair value as of December 31, 2020 and 2019, by caption on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2020				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	\$ 2	\$ —	\$ —	\$ —	\$ 2
Investments:					
Cash and cash equivalents	1,980	185	—	—	2,165
Fixed-income securities:					
U.S. government	—	450	—	—	450
U.S. government agencies	—	439	—	—	439
U.S. corporate	—	648	15	—	663
Foreign	—	46	—	—	46
Common and preferred stocks:					
U.S.	870	—	—	—	870
Foreign	529	—	25	—	554
Funds:					
Fixed-income	451	10	—	—	461
Equities	830	590	—	—	1,420
Less securities under lending agreement	(38)	—	—	—	(38)
Investments at NAV	—	—	—	7,290	7,290
Total investments	<u>4,622</u>	<u>2,368</u>	<u>40</u>	<u>7,290</u>	<u>14,320</u>
Investments under securities lending agreement	<u>38</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>38</u>
Other long-term assets:					
Trust receivables	74	29	83	—	186
Technology-based ventures	—	—	92	—	92
Total other long-term assets	<u>74</u>	<u>29</u>	<u>175</u>	<u>—</u>	<u>278</u>
Total assets at fair value	<u>\$ 4,736</u>	<u>\$ 2,397</u>	<u>\$ 215</u>	<u>\$ 7,290</u>	<u>\$ 14,638</u>
Liabilities:					
Securities lending payable	\$ 2	\$ —	\$ —	\$ —	2
Total liabilities at fair value	<u>\$ 2</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2019				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	\$ 1	\$ —	\$ —	\$ —	\$ 1
Investments:					
Cash and cash equivalents	1,286	18	—	—	1,304
Fixed-income securities:					
U.S. government	—	396	—	—	396
U.S. government agencies	—	376	—	—	376
U.S. corporate	—	436	22	—	458
Foreign	—	44	—	—	44
Common and preferred stocks:					
U.S.	686	—	—	—	686
Foreign	457	—	2	—	459
Funds:					
Fixed-income	505	—	—	—	505
Equities	661	605	—	—	1,266
Less securities under lending agreement	(19)	—	—	—	(19)
Investments at NAV	—	—	—	5,660	5,660
Total investments	<u>3,576</u>	<u>1,875</u>	<u>24</u>	<u>5,660</u>	<u>11,135</u>
Investments under securities lending agreement	<u>19</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>19</u>
Other long-term assets:					
Trust receivables	70	27	82	—	179
Technology-based ventures	—	—	64	—	64
Total other long-term assets	<u>70</u>	<u>27</u>	<u>146</u>	<u>—</u>	<u>243</u>
Total assets at fair value	<u>\$ 3,666</u>	<u>\$ 1,902</u>	<u>\$ 170</u>	<u>\$ 5,660</u>	<u>\$ 11,398</u>
Liabilities:					
Securities lending payable	\$ 1	\$ —	\$ —	\$ —	1
Total liabilities at fair value	<u>\$ 1</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 1</u>

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants,

Note 4. Fair Value Measurements (Continued)

dealers and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, comprised primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors which would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,421	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,869	1,447		
Total alternative investments	<u>\$ 7,290</u>	<u>\$ 1,546</u>		

At December 31, 2019, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 2,706	\$ 64	Monthly to annually	30–90 days
Private partnerships (b)	2,954	1,202		
Total alternative investments	<u>\$ 5,660</u>	<u>\$ 1,266</u>		

Note 4. Fair Value Measurements (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic’s ownership interest in partners’ capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic’s investment management program to minimize certain investment risks. During the years ended December 31, 2020 and 2019, the realized and unrealized loss from derivative contracts was not significant.

The carrying values of cash and cash equivalents, short-term investments, accounts receivable, other current assets, and accounts payable are reasonable estimates of their fair value due to the short-term nature of these financial instruments. The estimated fair value of long-term debt, based on quoted market prices for the same or similar issues (Level 2), was \$572 and \$311 more than its carrying value at December 31, 2020 and 2019, respectively. Other long-term assets and liabilities have a carrying value that approximates fair value.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2020 and 2019 was \$582 (5.7 percent) and \$527 (6.1 percent), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$884 and \$757, respectively, at December 31, 2020 and 2019, which includes segregated investments for deferred compensation plans of \$882 and \$739 at December 31, 2020 and 2019, respectively.

At December 31, 2020 and 2019, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$136 and \$131, respectively.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The Clinic had internally designated investment balances of \$2,806 and \$2,431 at December 31, 2020 and 2019, respectively, for research, education, and capital replacement and expansion.

Note 5. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

At December 31, 2020 and 2019, the aggregate market value of securities on loan under securities lending agreements totaled \$38 and \$19, respectively, and the total value of the collateral supporting the securities was \$39 and \$20, respectively, which represents 104 percent and 105 percent, respectively, of the value of the securities on loan at December 31, 2020 and 2019. The cash portion of the collateral supporting the securities as of December 31, 2020 and 2019 was \$2 and \$1, respectively. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 6. Property, Plant and Equipment, Net

Property, plant and equipment, net, at December 31 consisted of the following:

	2020	2019
Land	\$ 316	\$ 303
Buildings and improvements	6,454	6,134
Furniture and equipment	4,249	4,347
	<u>11,019</u>	<u>10,784</u>
Accumulated depreciation and amortization	(6,506)	(6,274)
	<u>4,513</u>	<u>4,510</u>
Construction in progress	451	324
Total property, plant and equipment	<u>\$ 4,964</u>	<u>\$ 4,834</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 6. Property, Plant and Equipment, Net (Continued)

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$914 and \$1,011 at December 31, 2020 and 2019, respectively. The total accumulated amortization was \$558 and \$609 at December 31, 2020 and 2019, respectively. Amortization expense for capitalized software was \$81 for 2020 and 2019.

Note 7. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income (UBI). The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2017 through 2019 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for the years 2003-2012. The results of this audit were ultimately litigated in U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS has appealed this decision. This ruling has been taken into consideration during the Clinic's determination of unrecognized tax benefits.

The Clinic has recorded \$6 reserve for uncertain tax positions, including interest and penalties, did not change significantly during the year ended December 31, 2020. As of December 31, 2020 and 2019, the reserve totaled \$20 and \$14, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2020	2019
Current—federal	\$ 53	\$ 17
Current—state	7	4
	<u>60</u>	<u>21</u>
Deferred—U.S. domestic	(20)	3
Total	<u>\$ 40</u>	<u>\$ 24</u>

Cash payments for income taxes were \$6 and \$34 for the years ended December 31, 2020 and 2019, respectively.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 7. Income Taxes (Continued)

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2020	2019
Deferred compensation	\$ 12	\$ 11
Pension	15	13
Postretirement benefits	7	5
Net operating loss	16	8
Other	11	9
Total deferred tax asset	61	46
Deferred tax liability	(7)	(6)
Valuation allowance	(13)	(21)
Net deferred tax asset	\$ 41	\$ 19

The Clinic had federal net operating losses of \$46 and \$40 at December 31, 2020 and 2019, respectively.

The Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017 repealed Net Operating Loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief and Economic Security Act (CARES Act) enacted on March 27, 2020 temporarily suspended TCJA repeal of NOL carrybacks allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to the five taxable years preceding the taxable year of such loss. The Clinic expects to fully utilize any NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 within one or more of the five tax years preceding the tax year of such loss.

The Clinic's valuation allowance for NOLs generated before January 1, 2020 were reversed. At December 31, 2020 the provisional amount recorded related to the reversal of the NOL valuation allowance was \$8.

The Clinic's NOLs generated before January 1, 2020 were remeasured based on the rates at which they are expected to reverse in the carryback periods, which is generally 35 percent. At December 31, 2020, the provisional amount recorded related to the remeasurement of the deferred tax balance was \$5.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 8. Financing

Long-term debt at December 31 consisted of the following:

		2020	2019
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 0.60% in 2020 and 1.50% in 2019), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2022 through 2032	Fixed	200	200
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	—
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rates of interest ranging from 4.00% to 4.93%, principal due in varying amounts from 2030 through 2048	Fixed	535	665
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with fixed interest rate of 5.00%, an effective rate of 2.97% in 2020 and 2019 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$55 in 2020 and \$59 in 2019)	Fixed	220	220
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.41% in 2020 and 1.38% in 2019), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.81% in 2020 and 1.53% in 2019), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.77% to 4.13%, principal due in varying amounts from 2039 through 2052	Fixed	950	950
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	915	415
Other notes payable		13	14
Unamortized discounts and premiums, net		52	57
Debt issuance cost		(12)	(13)
		<u>3,853</u>	<u>3,358</u>
Long-term variable-rate debt classified as current		(620)	(710)
Long-term debt subject to mandatory tender for purchase		(135)	—
Current maturities included in other current liabilities		(1)	(1)
Long-term debt, net of current portion		<u>\$ 3,097</u>	<u>\$ 2,647</u>

Note 8. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2020, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 of which \$140 will expire in January 2022 and \$90 will expire in January 2025. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2021. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The Clinic's \$135 City of Rochester, Minnesota Revenue Bonds Series 2011 C fixed rate bonds are subject to mandatory tender for purchase on November 15, 2021, and therefore, classified as current.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2021 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

In April 2020, the Clinic entered into a five-year bank loan agreement for \$100 at 1.80 percent. In May 2020, the Clinic entered into a seven-year bank loan agreement for \$100 at 1.99 percent. Also in May, the Clinic closed on a private placement transaction with an insurance company in the amount of \$200 with a 3.17 percent fixed rate with a final maturity in 2062. In September 2020, the Clinic closed on a private placement transaction with an insurance company in the amount of \$100 million with a 3.16 percent interest rate with a final maturity in 2060. The proceeds of the private placement and bank loans will be used for general corporate purposes. In addition, in May 2020, the Clinic refunded and modified \$130 of bonds by entering into a direct bank purchase for 10 years at 1.54 percent. The bond modification was accounted for as an extinguishment of debt. The loss on extinguishment was not significant.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2021 and \$230 may be due in years from 2022 to 2025.

Years ending December 31:

2021	\$	1
2022		38
2023		36
2024		18
2025		105

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 8. Financing (Continued)

Interest payments on long-term debt, net of amounts capitalized for 2020 and 2019, totaled \$106 and \$110, respectively. The amount of interest capitalized, net of related interest income, was \$3 during 2020 and \$6 during 2019. Interest expense totaled \$112 and \$111 for 2020 and 2019, respectively.

At December 31, 2020 and 2019, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2020 and 2019.

Note 9. Leases

At December 31, 2020 and 2019, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2020	2019
Operating lease expense	\$ 37	\$ 34
Finance lease expense:		
Amortization of right-of-use assets	\$ 10	\$ 9
Interest on lease liabilities	1	1
Total finance lease expense	\$ 11	\$ 10
Short-term lease expense	\$ 17	\$ 13

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2020	2019
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 53	\$ 45
Operating cash flows for finance leases	\$ 1	\$ 1
Financing cash flows for finance leases	\$ 15	\$ 8
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 11	\$ 37
Finance leases	\$ 12	\$ 15

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 9. Leases (Continued)

Consolidated supplemental statement of financial position information related to leases as of the year ended December 31 consisted of the following:

	2020	2019
Operating leases:		
Right-of-use assets	\$ 168	\$ 161
Other current liabilities	\$ 28	\$ 27
Other long-term liabilities	143	136
Total operating lease liabilities	\$ 171	\$ 163
Finance leases:		
Property, plant and equipment, gross	\$ 72	\$ 51
Accumulated depreciation	32	21
Property, plant and equipment, net	\$ 40	\$ 30
Other current liabilities	\$ 9	\$ 10
Other long-term liabilities	27	21
Total finance lease liabilities	\$ 36	\$ 31
Weighted average remaining lease years:		
Operating leases	10.02	8.79
Finance leases	8.06	8.21
Weighted average discount rate:		
Operating leases	3.54 %	2.77 %
Finance leases	3.49 %	3.76 %

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)****Note 9. Leases (Continued)**

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2021	\$ 33	\$ 11
2022	28	6
2023	21	5
2024	20	5
2025	16	3
Thereafter	91	12
Minimum lease payments	<u>209</u>	<u>42</u>
Less amount representing interest	38	6
Net minimum lease payments	<u>\$ 171</u>	<u>\$ 36</u>

Note 10. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2020	2019
Research	\$ 1,269	\$ 1,095
Education	296	201
Buildings and equipment	3	3
Charity care	11	10
Clinical	166	146
Other	1,061	976
Total designation for specified purpose	<u>\$ 2,806</u>	<u>\$ 2,431</u>

At December 31, board designated funds were classified as follows:

	2020	2019
Quasi-endowments	\$ 2,694	\$ 2,286
Professional liability reserve	112	99
Other reserves	—	46
Total	<u>\$ 2,806</u>	<u>\$ 2,431</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 11. Net Assets with Donor Restrictions

The Clinic receives contributions in support of research, education and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2020	2019
Subject to expenditure for specified purposes:		
Research	\$ 443	\$ 366
Education	42	40
Buildings and equipment	226	133
Charity care	36	39
Clinical	58	51
Other	37	15
Total expenditure for specified purposes	<u>842</u>	<u>644</u>
Subject to passage of time:		
Pledges and trusts	<u>470</u>	<u>348</u>
Endowments:		
Perpetual in nature:		
Research	1,078	1,006
Education	229	210
Charity care	14	14
Clinical	195	184
Other	29	29
Pledges and trusts	293	348
Total perpetual in nature	<u>1,838</u>	<u>1,791</u>
Subject to endowment spending policy:		
Research	670	502
Education	320	268
Charity care	36	26
Clinical	135	104
Other	38	32
Total subject to endowment spending policy	<u>1,199</u>	<u>932</u>
Total endowments	<u>3,037</u>	<u>2,723</u>
Total net assets with donor restrictions	<u>\$ 4,349</u>	<u>\$ 3,715</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 11. Net Assets with Donor Restrictions (Continued)

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2020		2019
Research	\$ 162	\$	161
Education	22		25
Buildings and equipment	22		56
Other	40		28
Total net assets released from donor restrictions	<u>\$ 246</u>	\$	<u>270</u>

Note 12. Endowment

The Clinic's endowment consists of approximately 2,200 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-

Note 12. Endowment (Continued)

endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2020, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,037	\$ 3,037
Quasi-endowments	2,694	—	2,694
Total funds	<u>\$ 2,694</u>	<u>\$ 3,037</u>	<u>\$ 5,731</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 12. Endowment (Continued)

Changes in endowment net assets for the year ended December 31, 2020 consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,286	\$ 2,723	\$ 5,009
Investment return:			
Investment income	20	20	40
Net appreciation (realized and unrealized)	345	351	696
Total investment return	365	371	736
Contributions	—	47	47
Appropriation of endowment assets for expenditure	(104)	(104)	(208)
Other changes:			
Transfers to create quasi-endowments	147	—	147
Endowment net assets, end of year	\$ 2,694	\$ 3,037	\$ 5,731

December 31, 2019, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 2,723	\$ 2,723
Quasi-endowments	2,286	—	2,286
Total funds	\$ 2,286	\$ 2,723	\$ 5,009

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 12. Endowment (Continued)

Changes in endowment net assets for the year ended December 31, 2019 consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,124	\$ 2,372	\$ 4,496
Investment return:			
Investment income	31	30	61
Net appreciation (realized and unrealized)	243	235	478
Total investment return	274	265	539
Contributions	—	180	180
Appropriation of endowment assets for expenditure	(246)	(94)	(340)
Other changes:			
Transfers to create quasi endowments	134	—	134
Endowment net assets, end of year	\$ 2,286	\$ 2,723	\$ 5,009

Note 13. Promises to Give

At December 31, outstanding pledges from various corporations, foundations and individuals, included in other receivables and other long-term assets, were as follows:

	2020	2019
Pledges due:		
In less than one year	\$ 234	\$ 185
In one to five years	362	330
In more than five years	45	53
	641	568
Allowance for uncollectible pledges and discounts	(72)	(62)
Total	\$ 569	\$ 506

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges' due dates and established in the year the pledge is received.

Notes to Consolidated Financial Statements (In Millions)

Note 13. Promises to Give (Continued)

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 3.56 percent and 4.33 percent at December 31, 2020 and 2019, respectively. During the years ended December 31, 2020 and 2019, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$186 and \$179 at December 31, 2020 and 2019, respectively.

Note 14. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2020 and 2019 supported the following programs and functions:

	2020							Total expenses
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	
Salaries and benefits	\$ 6,757	\$ 173	\$ 608	\$ 305	\$ 50	\$ 19	\$ 152	\$ 8,064
Supplies and services	2,730	1,006	224	52	9	6	72	4,099
Depreciation and amortization	514	8	64	12	10	1	2	611
Facilities	228	5	16	11	14	1	1	276
Finance and investment	138	1	18	1	1	—	(27)	132
Total	\$ 10,367	\$ 1,193	\$ 930	\$ 381	\$ 84	\$ 27	\$ 200	\$ 13,182

	2019							Total expenses
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	
Salaries and benefits	\$ 6,339	\$ 181	\$ 553	\$ 286	\$ 30	\$ 13	\$ 268	\$ 7,670
Supplies and services	2,815	853	247	68	37	10	46	4,076
Depreciation and amortization	496	9	59	11	9	1	2	587
Facilities	240	6	17	11	13	1	2	290
Finance and investment	128	1	15	1	1	—	(13)	133
Total	\$ 10,018	\$ 1,050	\$ 891	\$ 377	\$ 90	\$ 25	\$ 305	\$ 12,756

Note 15. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2020 and 2019 are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$4,837 and \$4,408 and unrecognized prior service benefit of \$160 and \$229. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants. The unrecognized actuarial losses and prior service benefit included in net assets are expected to be recognized in net periodic pension cost during the year ended December 31, 2021, in the amount of \$338 and \$51, respectively.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2020 and 2019 included the following:

	2020	2019
Current-year actuarial gain (loss)	\$ (701)	\$ (1,121)
Amortization of actuarial loss	274	152
Amortization of prior service credit	(69)	(69)
Pension and other postretirement benefit adjustments	\$ (496)	\$ (1,038)

Pension plans:

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

	2020	2019
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 10,705	\$ 8,866
Service cost	553	447
Interest cost	371	374
Actuarial loss	1,388	1,493
Benefits paid	(657)	(476)
Estimated benefit obligation at end of year	<u>\$ 12,360</u>	<u>\$ 10,705</u>
Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 9,334	\$ 8,084
Actual return on plan assets	1,409	1,180
Employer contributions	556	545
Benefits paid	(657)	(476)
Fair value of plan assets at end of year	<u>\$ 10,642</u>	<u>\$ 9,334</u>
	2020	2019
Funded status of the plans	<u>\$ (1,718)</u>	<u>\$ (1,371)</u>
Accumulated benefit obligation	<u>\$ (11,596)</u>	<u>\$ 10,173</u>
Amounts recognized in the consolidated statements of financial position consist of the following at December 31:		
	2020	2019
Noncurrent liabilities	<u>\$ (1,718)</u>	<u>\$ (1,371)</u>
Net amount recognized	<u>\$ (1,718)</u>	<u>\$ (1,371)</u>

Note 15. Employee Benefit Programs (Continued)

Components of net periodic benefit cost are as follows at December 31:

	2020	2019
Service cost	\$ 553	\$ 447
Interest cost	371	374
Expected return on plan assets	(678)	(635)
Amortization of unrecognized:		
Prior service benefit	(50)	(50)
Net actuarial loss	244	142
Net periodic benefit cost	<u>\$ 440</u>	<u>\$ 278</u>

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$10,519 of the \$10,642 in combined plan assets at December 31, 2020, and \$9,216 of the \$9,334 in combined plan assets at December 31, 2019. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 30 percent (with a target allocation of 22.5 percent), and exposure to absolute return strategies is limited to a maximum of 35 percent (with a target of 27.5 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

The fair values of the Plan's assets at December 31, 2020, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 616	\$ 41	\$ —	\$ —	\$ 657
Fixed-income securities:					
U.S. government	—	146	—	—	146
U.S. government agencies	—	126	—	—	126
U.S. corporate	—	406	5	—	411
Foreign	—	33	—	—	33
Common and preferred stocks:					
U.S.	926	—	—	—	926
Foreign	639	—	—	—	639
Funds:					
Fixed-income	132	10	—	—	142
Equities	42	654	—	—	696
Foreign	79	—	—	—	79
Investments at NAV	—	—	—	6,664	6,664
Total investments	\$ 2,434	\$ 1,416	\$ 5	\$ 6,664	\$ 10,519

The fair values of the Plan's assets at December 31, 2019, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 423	\$ 265	\$ —	\$ —	\$ 688
Fixed-income securities:					
U.S. government	—	100	—	—	100
U.S. government agencies	—	146	—	—	146
U.S. corporate	—	344	7	—	351
Foreign	—	37	—	—	37
Common and preferred stocks:					
U.S.	793	—	—	—	793
Foreign	567	—	—	—	567
Funds:					
Fixed-income	119	—	—	—	119
Equities	36	615	—	—	651
Foreign	67	—	—	—	67
Investments at NAV	—	—	—	5,697	5,697
Total investments	\$ 2,005	\$ 1,507	\$ 7	\$ 5,697	\$ 9,216

Note 15. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2020 or 2019.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,613	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,051	1,281		
	<u>\$ 6,664</u>	<u>\$ 1,380</u>		

At December 31, 2019, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,141	\$ 64	Monthly to annually	30–90 days
Private partnerships (b)	2,556	1,185		
	<u>\$ 5,697</u>	<u>\$ 1,249</u>		

Note 15. Employee Benefit Programs (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan’s ownership interest in partners’ capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2021.

Other postretirement benefits:

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

	2020	2019
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 1,180	\$ 1,008
Service cost	9	9
Interest cost	39	43
Plan participants' contributions	31	30
Amendments	—	—
Medicare subsidy	3	3
Actuarial loss	46	178
Benefits paid	(80)	(91)
Estimated benefit obligation at end of year	<u>\$ 1,228</u>	<u>\$ 1,180</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	49	58
Plan participants' contributions	31	30
Medicare subsidy	—	3
Benefits paid	(80)	(91)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (1,228)</u>	<u>\$ (1,180)</u>

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2020	2019
Current liabilities	\$ (49)	\$ (51)
Noncurrent liabilities	(1,179)	(1,129)
Net amount recognized	<u>\$ (1,228)</u>	<u>\$ (1,180)</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2020	2019
Service cost	\$ 9	\$ 9
Interest cost	39	43
Amortization of:		
Unrecognized prior service benefit	(19)	(19)
Unrecognized net actuarial loss	30	11
Net periodic benefit cost for other postretirement benefits	<u>\$ 59</u>	<u>\$ 44</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:

2021	\$	3
2022		3
2023		3
2024		3
2025		3
2026–2030		16

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent. A one-percentage-point change in the assumed health care cost trend rate would have the following effects:

	One-Percentage- Point Increase	One-Percentage- Point Decrease
Effect on total service and interest cost components in 2020	\$ 2	\$ (2)
Effect on postretirement benefit obligation at December 31, 2020	48	(41)

Note 15. Employee Benefit Programs (Continued)

Pension and postretirement benefits:

Assumptions: Weighted-average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2020	2019	2020	2019
Discount rate	2.91%	3.56%	2.70%	3.41%
Rate of compensation increase	3.70%	3.58%	N/A	N/A

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2020	2019	2020	2019
Discount rate	3.56%	4.33%	3.41%	4.35%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.58%	3.53%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash flows:

Contributions: The Clinic expects to contribute \$373 to its pension plans in 2021.

Note 15. Employee Benefit Programs (Continued)

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2021	\$ 663	\$ 50
2022	615	53
2023	607	55
2024	600	58
2025	642	59
2026–2030	3,175	317

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$117 and \$110 for 2020 and 2019, respectively.

Note 16. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$118 and \$111 at December 31, 2020 and 2019, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 16. General and Professional Liability Insurance

Activity in the liability is summarized as follows for the years ended December 31:

	2020	2019
Balance, beginning of year	\$ 111	\$ 101
Incurred related to captive insurance company liability:		
Current year	26	23
Prior years	(4)	4
Total incurred	22	27
Paid related to captive insurance company liability:		
Current year	—	(1)
Prior years	(19)	(15)
Total paid	(19)	(16)
Net change in self-insurance liability	4	(1)
Balance, end of year	\$ 118	\$ 111

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2020	2019
Pledges receivable	\$ 234	\$ 185
Grants receivable	134	114
Other tax receivable	31	—
Royalty receivable	15	32
Other	162	127
Total other receivables	\$ 576	\$ 458

At December 31, other current assets consisted of the following:

	2020	2019
Inventories	\$ 186	\$ 149
Prepaid expenses	66	52
Total other current assets	\$ 252	\$ 201

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other long-term assets consisted of the following:

	2020	2019
Pledges receivable	\$ 335	\$ 321
Trust receivables	186	179
Operating lease right-of-use asset	168	161
Oil and gas interests	165	155
Technology-based ventures	92	64
Investment in joint venture	89	—
Long-term portion of deferred tax asset	20	27
Other	149	116
Total other long-term assets	<u>\$ 1,204</u>	<u>\$ 1,023</u>

At December 31, other current liabilities consisted of the following:

	2020	2019
Oil and gas liability	\$ 85	\$ 89
Other taxes	81	86
Current portion of long-term disability	38	35
Current portion of professional and general liability	35	31
Short-term disability	33	32
Real estate tax accrual	28	24
Operating lease liability	28	27
Refunds/recoupments	21	24
Current portion of workers' compensation liability	11	17
Finance lease liability	9	10
Other	101	98
Total other current liabilities	<u>\$ 470</u>	<u>\$ 473</u>

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other long-term liabilities consisted of the following:

	2020	2019
Deferred compensation	\$ 882	\$ 739
Long-term disability	211	182
Operating lease liability	143	136
Electronic medical record	105	110
Retirement community obligations	87	38
Professional and general liability	83	80
Gift annuities	67	69
Deferred gain	56	—
Financing obligations	54	57
Trust obligations	53	47
Asset retirement obligation	52	22
Workers' compensation liability	32	26
Finance lease liability	27	21
Contract deposit	22	22
Other	90	85
Total other long-term liabilities	<u>\$ 1,964</u>	<u>\$ 1,634</u>

Note 18. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2020	2019
Retail pharmacy sales	\$ 393	\$ 346
Provider relief funds and other support	199	—
Royalties	129	117
Retail stores	57	60
Technology commercialization, health information and medical products	49	69
Oil- and gas-producing activities	46	28
Cafeteria revenue	26	37
Graduate medical and other education revenue	22	41
Other	300	320
Total other revenue	<u>\$ 1,221</u>	<u>\$ 1,018</u>

Note 19. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2020 is \$1,363, all of which is expected to be expended over the next three to five years.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Note 20. COVID-19

In March 2020, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) a pandemic. The Center for Disease Control (CDC) confirmed its spread to the United States and it was declared a national public health emergency, followed by several state emergency declarations, and the Centers for Medicare and Medicaid Services (CMS) issuing guidance regarding elective procedures. Several national and international travel restrictions were put in place and the governors in the states in which the Clinic has operations issued executive orders postponing non-essential or elective surgeries. In response, the Clinic took appropriate measures to respond to the anticipated revenue shortfalls; including reducing supplemental and contract workforce, halting most construction projects, deferring or delaying most strategic initiatives, and announcing temporary salary and staff reductions. In May 2020, elective surgeries were resumed as governmental order restrictions on elective surgeries were modified.

Beginning in April 2020, the Clinic started receiving provider relief funds totaling \$338 from various provisions in the CARES Act of which \$182 was recognized as other revenue in the consolidated statement of activities and the remaining \$156 was returned in December 2020. Additionally, in April 2020, the Clinic received \$915 of Medicare advance payments as part of the CMS Accelerated and Advance Payments Program, and subsequently returned the \$915 of the CMS Accelerated and Advance Program payments in July 2020.

The Clinic was well-prepared and ready to treat patients with COVID-19 across the organization, especially those with serious or complex medical conditions. By the end of May 2020, the governors had relaxed restrictions on non-essential or elective surgeries. The Clinic resumed to safely caring for patients facing non-COVID-19 conditions who are in need of the unique and specialized care offered by the Clinic. However, COVID-19 could still negatively affect the operating margins and financial results of the Clinic, as the duration of the pandemic is unknown.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 21. Joint Venture and Related Party

The Clinic has entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC (SEHA) to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates. The Clinic funded a 25% equity position in the joint venture (SSMC LLC) with cash and other intangibles. The Clinic's equity position is accounted for using the equity method of accounting for investments. In addition to the joint venture agreement, the Clinic has entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC all executed on November 25, 2019.

The joint venture has an initial commitment period of twenty years and may be extended by ten years.

The Clinic had a \$150 conditional pledge from the joint venture at December 31, 2020 and 2019. The brand license and hospital expertise agreements are effective January 2021.

Note 22. U.S. Department of Education Financial Responsibility Ratio Information

The following information is required by the U.S. Department of Education for the year ended December 31,

	2020
Net assets with temporary donor restrictions	\$ 2,511
Intangible assets	\$ 1
Post-employment and retirement liabilities	
Accrued Pension and postretirement benefits, net of current portion	\$ 2,897
Postretirement benefits, current portion	49
Total post-employment and retirement liabilities	\$ 2,946
Property, plant and equipment, including construction in progress and right of use asset, net of accumulated depreciation	
Property, plant and equipment, net	\$ 4,964
Right-of-use asset	168
Total Property, plant and equipment, including construction in progress and right of use asset, net of accumulated depreciation	\$ 5,132
Long-term debt obtained for long term purposes	
Long-term debt	\$ 3,853
Operating lease liabilities	171
Finance lease liabilities	36
Total long-term debt obtained for long term purposes	\$ 4,060

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 22. U.S. Department of Education Financial Responsibility Ratio Information (Continued)

Expenses and losses without donor restrictions	
Operating expenses	\$ 13,182
Contributions not available for current activities, net	21
Income tax expense	40
Pension and other postretirement benefit adjustments	496
Total expenses and losses without donor restrictions	<u>\$ 13,739</u>
Revenue without donor restrictions	
Total revenue, gains and other support	\$ 13,866
Unallocated investment return, net	1,144
Benefit credit	62
Other	4
Total revenue without donor restrictions	<u>\$ 15,076</u>

Supplementary Information

Mayo Clinic

Financial Responsibility Supplemental Schedule Required by the U.S. Department of Education Year Ended December 31, 2020 (In Millions)

Ratio Element	Reference to Financial Statements and/or Notes	2020
Primary Reserve Ratio		
Expendable Net Assets		
Net assets without donor restrictions	Consolidated Statements of Financial Position	\$ 8,016
Net assets with temporary donor restrictions	Note 22 - U.S. Department of Education	2,511
Term endowments with donor restrictions	Note 11 - Net Assets with Donor Restrictions	1,199
Intangible assets	Note 22 - U.S. Department of Education	1
Property, plant and equipment, including construction in progress, and right of use asset, net of accumulated depreciation	Note 22 - U.S. Department of Education	5,132
Long-term debt obtained for long term purposes	Note 22 - U.S. Department of Education	4,060
Post-employment and retirement liabilities	Note 22 - U.S. Department of Education	2,946
Total Expenses and Losses		
Total expenses and losses without donor restrictions	Note 22 - U.S. Department of Education	13,739
Equity Ratio		
Modified Net Assets		
Net assets with and without donor restrictions	Consolidated Statements of Financial Position	12,365
Intangible assets	Note 22 - U.S. Department of Education	1
Modified Assets		
Total assets	Consolidated Statements of Financial Position	23,184
Intangible assets	Note 22 - U.S. Department of Education	1
Net Income Ratio		
Change in net assets without donor restrictions	Consolidated Statements of Activities	1,337
Total revenue without donor restrictions	Note 22 - U.S. Department of Education	15,076

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF COMMERCE									
CLUSTER GRANTS	11.020	ED19HDQ0200083				\$372,343	\$372,343	N/A	\$0
TOTAL DEPARTMENT OF COMMERCE						<u>\$372,343</u>			
DEPARTMENT OF DEFENSE									
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	BMT CTN 1702	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1702		\$10,245	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	BMT CTN 1703/1801	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1703/1801		\$6,668	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	BMT CTN 1704	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1704		\$10,359	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-16-1-3173				\$3,413	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-17-1-2165	RENSSELAER POLYTECHNIC INSTITUTE	N00014-17-1-2165		\$37,479	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-18-D-7001			\$319,321	\$1,727,901	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-19-C-2007				\$1,364,898	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-19-C-2017				\$539,718	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-19-C-2017				\$674,941	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300	N00014-20-1-2726				\$51,022	\$4,426,644	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-13-1-0259	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	W81XWH-13-1-0259		\$11,950	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-14-1-0563	UNIVERSITY OF DELAWARE	W81XWH-14-1-0563		\$5,500	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-14-2-0003	WAKE FOREST	W81XWH-14-2-0003		\$174,048	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0115				\$60,429	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0257				\$1,133	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0269	BRIGHAM AND WOMEN'S HOSPITAL	W81XWH-15-1-0269		\$168,441	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0292			-\$43,533	\$4,638,481	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0293			\$305,061	\$1,374,535	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-1-0705	UNIVERSITY OF ALABAMA	W81XWH-15-1-0705		\$4,748	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-2-0068	VANDERBILT UNIVERSITY	W81XWH-15-2-0068		\$6,733	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-15-2-0071			\$388,260	\$528,688	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0265				\$192,630	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0266				\$206,981	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0268				\$397,847	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0269				\$211,014	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0540				\$481,180	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-1-0668				\$18,877	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-16-2-0030				\$268	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420	W81XWH-17-1-0248				\$316,244	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0249				\$154,567	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0498				\$59,282	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0546				\$57,638	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-17-1-0644</i>	<i>MASSACHUSETTS EYE & EAR INFIRMARY</i>	<i>W81XWH-17-1-0644</i>		<i>\$618</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-17-2-0037</i>	<i>UNIVERSITY OF ALABAMA</i>	<i>W81XWH-17-2-0037</i>		<i>\$28,731</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-17-2-0073</i>	<i>UNIVERSITY OF PITTSBURGH</i>	<i>W81XWH-17-2-0073</i>		<i>\$50,608</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0074				\$74,872	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0218				\$113,023	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0292				\$178,936	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0297				\$202,349	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0345				\$249,502	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0504				\$43,541	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				\$650,033	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564				\$1,128,846	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0650				\$118,586	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0652				\$144,009	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0676				\$281,022	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0760			\$349,172	\$477,735	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0029				\$191,884	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0081				\$179,272	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-19-1-0139</i>	<i>CONTRAFECT CORPORATION</i>	<i>W81XWH-19-1-0139</i>		<i>\$36,218</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0193			\$116,897	\$314,353	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534			\$402,128	\$1,128,904	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0583				\$778,592	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-19-1-0591</i>	<i>FLOSONICS MEDICAL</i>	<i>W81XWH-19-1-0591</i>		<i>\$73,950</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0680				\$313,820	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0756				\$258,395	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0214				\$241,015	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0215				\$98,694	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0262			\$67,320	\$218,304	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0322				\$23,899	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0400				\$228,706	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				\$32,345	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-20-1-0682</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>W81XWH-20-1-0682</i>		<i>\$4,727</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				\$10,778	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0886				\$27,136	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0903				\$28,831	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0923				\$28,940	\$17,039,594	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>W81XWH-20-P-0017</i>	<i>VIVONICS, INC.</i>	<i>W81XWH-20-P-0017</i>		<i>\$7,186</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	<i>12.420</i>	<i>WEI1872</i>	<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>	<i>WEI1872</i>		<i>\$20</i>	<i>\$17,039,594</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS</i>	<i>12.750</i>	<i>HJMF #5</i>	<i>HENRY M. JACKSON FOUNDATION</i>	<i>HJMF #5</i>		<i>\$15,251</i>	<i>\$15,251</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>RESEARCH AND TECHNOLOGY DEVELOPMENT</i>	<i>12.910</i>	<i>DARPA</i>	<i>UNIVERSITY OF OXFORD</i>	<i>DARPA</i>		<i>\$137,122</i>	<i>\$149,175</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>RESEARCH AND TECHNOLOGY DEVELOPMENT</i>	<i>12.910</i>	<i>N66001-17-2-4010</i>	<i>UNIVERSITY OF WISCONSIN-MADISON</i>	<i>N66001-17-2-4010</i>		<i>\$11,813</i>	<i>\$149,175</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>RESEARCH AND TECHNOLOGY DEVELOPMENT</i>	<i>12.910</i>	<i>N66001-17-2-4018</i>	<i>ARIZONA STATE UNIVERSITY</i>	<i>N66001-17-2-4018</i>		<i>\$240</i>	<i>\$149,175</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>12.RD</i>	<i>2140-S001</i>	<i>VIVONICS, INC.</i>	<i>2140-S001</i>		<i>\$4,480</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	12.RD	75D30119C06088			\$863,143	\$1,410,365	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	75D30119P06070				\$17,706	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>12.RD</i>	<i>75D30120C07725</i>	<i>CHILDREN'S HOSPITAL OF BOSTON</i>	<i>75D30120C07725</i>		<i>\$8,770</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>12.RD</i>	<i>75F40119C10080</i>	<i>DUKE UNIVERSITY</i>	<i>75F40119C10080</i>		<i>\$24,524</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>12.RD</i>	<i>75N93019C00052</i>	<i>UNIVERSITY OF GEORGIA</i>	<i>75N93019C00052</i>		<i>\$251,597</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>12.RD</i>	<i>80NSSC20C0529</i>	<i>AGNI MEDICAL LLC</i>	<i>80NSSC20C0529</i>		<i>\$9,857</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	12.RD	FA8650-19-C-6979				\$678,819	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	H98230-13-D-0123				\$1,733,674	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	H98230-18-D-0024			\$148,742	\$3,854,110	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	MTEC 2020-625				\$48,542	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	N68936-19-C-0003				\$95,452	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	N68936-19-C-0003				\$683,491	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>12.RD</i>	<i>TXS0163614</i>	<i>WYLE LABORATORIES, INC.</i>	<i>TXS0163614</i>		<i>\$60,255</i>	<i>\$9,533,979</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CONTRACT	12.RD	VA263-17-Q-0877				\$11,239	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	W81XWH-15-9-0001	APPLIED RESEARCH ASSOCIATES, INC.	W81XWH-15-9-0001		\$334,622	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	W81XWH-17-C-0029	THE GENEVA FOUNDATION	W81XWH-17-C-0029		\$57,032	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	W81XWH-17-C-0253	THE GENEVA FOUNDATION	W81XWH-17-C-0253		\$56,559	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	W81XWH-18-2-0076	DARTMOUTH COLLEGE	W81XWH-18-2-0076		\$183,164	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	12.RD	W81XWH-20-1-0171	SOUTHWEST AUTISM RESEARCH & RESOURCE CENTER	W81XWH-20-1-0171		\$9,721	\$9,533,979	RESEARCH AND DEVELOPMENT	\$380,451,621
TOTAL DEPARTMENT OF DEFENSE						<u>\$2,916,511</u>	<u>\$31,164,643</u>		
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157					\$735,109	\$735,109	N/A	\$0
SECTION 8 HOUSING CHOICE VOUCHERS	14.871					\$190,556	\$190,556	HOUSING VOUCHER CLUSTER	\$190,556
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT							<u>\$925,665</u>		
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575					\$107,411	\$107,411	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE							<u>\$107,411</u>		
DEPARTMENT OF TREASURY									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19	WISCONSIN DEPARTMENT OF HEALTH SERVICES	NONE		\$263,819	\$263,819	N/A	\$0
TOTAL DEPARTMENT OF TREASURY							<u>\$263,819</u>		
FEDERAL COMMUNICATIONS COMMISSION									
COVID-19 TELEHEALTH PROGRAM	32.006	COVID-19				\$981,523	\$981,523	N/A	\$0
TOTAL FEDERAL COMMUNICATIONS COMMISSION							<u>\$981,523</u>		
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	80NSSC20K0116				\$206,694	\$206,694	RESEARCH AND DEVELOPMENT	\$380,451,621
EXPLORATION	43.003	NNX16AK50G				\$10,502	\$10,502	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	43.RD	80JSC019P0041			\$90,333	\$189,056	\$189,056	RESEARCH AND DEVELOPMENT	\$380,451,621
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						<u>\$90,333</u>	<u>\$406,252</u>		
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF #8	MEDICOOL TECHNOLOGIES INC.	NSF #8		\$19,218	\$60,559	RESEARCH AND DEVELOPMENT	\$380,451,621
ENGINEERING	47.041	NSF-GRFP18				\$41,341	\$60,559	RESEARCH AND DEVELOPMENT	\$380,451,621
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 1903135	ARIZONA STATE UNIVERSITY	NSF 1903135		\$129,575	\$129,575	RESEARCH AND DEVELOPMENT	\$380,451,621
GEOSCIENCES	47.050	NSF 1719325	ARIZONA STATE UNIVERSITY	NSF 1719325		\$15,663	\$15,663	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1602198				\$13,993	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1624615				\$91,215	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1837572				\$116,162	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1901046	PURDUE UNIVERSITY	NSF 1901046		\$25,838	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2002540	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	NSF 2002540		\$1,199	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339				\$48,460	\$296,867	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOLOGICAL SCIENCES	47.074	NSF 1744098			\$62,079	\$110,462	\$110,462	RESEARCH AND DEVELOPMENT	\$380,451,621
EDUCATION AND HUMAN RESOURCES	47.076	NSF 1744557				\$35,454	\$77,487	RESEARCH AND DEVELOPMENT	\$380,451,621
EDUCATION AND HUMAN RESOURCES	47.076	NSF-GRFP19				\$42,033	\$77,487	RESEARCH AND DEVELOPMENT	\$380,451,621
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-20-66590	UNIVERSITY OF WISCONSIN-MADISON	OISE-20-66590		\$4,921	\$4,921	RESEARCH AND DEVELOPMENT	\$380,451,621
TOTAL NATIONAL SCIENCE FOUNDATION						\$62,079	\$695,534		
DEPARTMENT OF VETERANS AFFAIRS									
CONTRACT	64.RD	IPA AGREEMENT-KAUFMAN				\$50,828	\$99,453	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	64.RD	IPA AGREEMENT-MORROW				\$10,971	\$99,453	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	64.RD	IPA AGREEMENT-PERSAD				\$37,654	\$99,453	RESEARCH AND DEVELOPMENT	\$380,451,621
TOTAL DEPARTMENT OF VETERANS AFFAIRS							\$99,453		
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063					\$58,248	\$58,248	STUDENT FINANCIAL ASSISTANCE	\$12,902,948
FEDERAL DIRECT STUDENT LOANS	84.268					\$12,844,700	\$12,844,700	STUDENT FINANCIAL ASSISTANCE	\$12,902,948
COVID-19 EDUCATION STABILIZATION FUND	84.425	COVID-19, 84.425E, CARES ACT GRANT 041020				\$164,147	\$328,294	N/A	\$0
COVID-19 EDUCATION STABILIZATION FUND	84.425	COVID-19, 84.425F, CARES ACT RELIEF INSTL FUNDS				\$164,147	\$328,294	N/A	\$0
TOTAL DEPARTMENT OF EDUCATION							\$13,231,242		
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	DA37378	UNIVERSITY OF ARIZONA	DA37378		\$687	\$687	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	DD01155	GREAT LAKES HEMOPHILIA FOUNDATION	DD01155		\$26,539	\$26,539	RESEARCH AND DEVELOPMENT	\$380,451,621
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	FD004781				\$7,220	\$2,279,127	RESEARCH AND DEVELOPMENT	\$380,451,621
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	FD006102	ARIZONA STATE UNIVERSITY	FD006102		\$200,869	\$2,279,127	RESEARCH AND DEVELOPMENT	\$380,451,621
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	FD04086	UNIVERSITY OF COLORADO	FD04086		\$3,303	\$2,279,127	RESEARCH AND DEVELOPMENT	\$380,451,621
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	FD05938	YALE UNIVERSITY	FD05938	\$429,500	\$1,754,496	\$2,279,127	RESEARCH AND DEVELOPMENT	\$380,451,621
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	FD06292	MEDICAL DEVICE INNOVATION	FD06292	\$100,000	\$313,239	\$2,279,127	RESEARCH AND DEVELOPMENT	\$380,451,621
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24052	GREAT LAKES HEMOPHILIA FOUNDATION	MC24052		\$31,028	\$31,028	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE28105				\$362,007	\$363,313	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ORAL DISEASES AND DISORDERS RESEARCH</i>	93.121	DE29632	RECOMBINETICS, INC.	DE29632		\$1,306	\$363,313	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>GRANTS TO INCREASE ORGAN DONATIONS</i>	93.134	EHS32756	ARBOR RESEARCH COLLABORATIVE	EHS32756		\$54,139	\$86,724	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>GRANTS TO INCREASE ORGAN DONATIONS</i>	93.134	HS33878	UNIVERSITY OF KANSAS MEDICAL CENTER	HS33878		\$32,585	\$86,724	RESEARCH AND DEVELOPMENT	\$380,451,621
HUMAN GENOME RESEARCH	93.172	HG06379			\$32,848	\$786,961	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>HUMAN GENOME RESEARCH</i>	93.172	HG06834	BRIGHAM AND WOMEN'S HOSPITAL	HG06834		\$123,367	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>HUMAN GENOME RESEARCH</i>	93.172	HG08988	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION	HG08988		\$47,337	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
HUMAN GENOME RESEARCH	93.172	HG09542				\$153,302	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>HUMAN GENOME RESEARCH</i>	93.172	HG09668	CASE WESTERN RESERVE UNIVERSITY	HG09668		\$43,547	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>HUMAN GENOME RESEARCH</i>	93.172	HG10004	CHILDREN'S HOSPITAL OF BOSTON	HG10004		\$16,750	\$1,171,264	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				\$753,912	\$1,312,125	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS</i>	93.173	DC13115	NORTHWESTERN UNIVERSITY	DC13115		\$44,188	\$1,312,125	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				\$514,025	\$1,312,125	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH</i>	93.213	AI134590	IMMUNOGEN X	AI134590		\$18,472	\$592,661	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010875				\$309,332	\$592,661	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH</i>	93.213	AT09637	IMMUNOGEN X MINNESOTA	AT09637		\$180,359	\$592,661	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH</i>	93.213	AT09665	HEALTHSOLUTIONS CORPORATION	AT09665		\$3,580	\$592,661	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH</i>	93.213	AT09844	NEW YORK SCHOOL OF MEDICINE	AT09844		\$80,918	\$592,661	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	AHRQ-CEPI-19				\$16,754	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS23418	DUKE UNIVERSITY	HS23418		\$177,916	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS24075	DARTMOUTH COLLEGE	HS24075		\$99,310	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS25164	UNIVERSITY OF MINNESOTA	HS25164		\$8,027	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25402				\$352,718	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS25412	VIRGINIA COMMONWEALTH UNIVERSITY	HS25412		\$91,899	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS26379	UNIVERSITY OF MINNESOTA	HS26379		\$133,198	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26609			\$105,832	\$589,981	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES</i>	93.226	HS26622	UNIVERSITY OF MICHIGAN	HS26622		\$227,052	\$1,696,855	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134808				\$567,560	\$1,455,788	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134885				\$569,891	\$1,455,788	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL65176				\$318,337	\$1,455,788	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MENTAL HEALTH RESEARCH GRANTS</i>	93.242	MH106876	YALE UNIVERSITY	MH106876		\$106,527	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MENTAL HEALTH RESEARCH GRANTS</i>	93.242	MH108222	EVIDENCE-BASED PRACTICE INSTITUTE, INC.	MH108222		\$18,550	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>MENTAL HEALTH RESEARCH GRANTS</i>	93.242	MH108348	DUKE UNIVERSITY	MH108348		\$58,612	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MENTAL HEALTH RESEARCH GRANTS	93.242	MH109190	MINNESOTA HEALTHSOLUTIONS CORPORATION	MH109190		\$34,091	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH109648	YALE UNIVERSITY	MH109648		\$106,949	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH113700			\$151,067	\$576,322	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114899				\$40,961	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114967	COLUMBIA UNIVERSITY	MH114967		\$203,417	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				\$242,555	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH122258			\$95,295	\$300,124	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655				\$6,522	\$1,694,630	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA18779				\$389,349	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA20735	UNIVERSITY OF NEBRASKA	AA20735		\$265,331	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				\$299,125	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA21788				\$200,044	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA26875				\$224,162	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA26877				\$138,841	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA26886				\$78,746	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA26887				\$243,414	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				\$282,456	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA27179			\$168,920	\$534,073	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				\$654,895	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA27487			\$43,021	\$707,186	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA27773				\$117,225	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				\$98,081	\$4,232,928	RESEARCH AND DEVELOPMENT	\$380,451,621
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA37299				\$102,722	\$797,090	RESEARCH AND DEVELOPMENT	\$380,451,621
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				\$503,353	\$797,090	RESEARCH AND DEVELOPMENT	\$380,451,621
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA46008			\$123,323	\$167,163	\$797,090	RESEARCH AND DEVELOPMENT	\$380,451,621
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA47003	YALE UNIVERSITY	DA47003		\$23,852	\$797,090	RESEARCH AND DEVELOPMENT	\$380,451,621
CENTERS FOR DISEASE CONTROL AND PREVENTION INVESTIGATIONS AND TECHNICAL ASSISTANCE	93.283	DP06491				\$141,675	\$141,675	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				\$369,044	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB017095				\$47,484	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				\$630,174	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				\$445,768	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17213				\$52,598	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17270	THE RESEARCH FOUNDATION FOR SUNY	EB17270		\$6,880	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB18965			\$139,330	\$333,557	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403				\$446,148	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19947				\$84,665	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB21027	UNIVERSITY OF MINNESOTA	EB21027		\$47,523	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24071				\$38,765	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24403			\$323,655	\$731,499	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24450			\$475,063	\$743,347	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26284	UNIVERSITY OF SOUTHERN CALIFORNIA	EB26284		\$108,364	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26780	UNIVERSITY OF CALIFORNIA LOS ANGELES	EB26780		\$679	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26780				\$50,187	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26976	GE CAPITAL	EB26976		\$271,323	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27064				\$352,157	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27742				\$32,651	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28101			\$168,057	\$497,751	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				\$355,878	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28591				\$393,255	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				\$307,374	\$6,347,071	RESEARCH AND DEVELOPMENT	\$380,451,621
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	2H3HRH00007-18-00				\$94,276	\$1,106,080	N/A	\$0
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	STATE OF MINNESOTA; MINNESOTA DEPARTMENT OF HEALTH	1 H3JRH37452-01-00		\$590,219	\$1,106,080	N/A	\$0
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	UNIVERSITY OF WISCONSIN SYSTEM	610		\$84,317	\$1,106,080	N/A	\$0

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	UNIVERSITY OF WISCONSIN SYSTEM	572		\$84,317	\$1,106,080	N/A	\$0
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	UNIVERSITY OF WISCONSIN SYSTEM	600		\$84,317	\$1,106,080	N/A	\$0
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	UNIVERSITY OF WISCONSIN SYSTEM	608		\$84,317	\$1,106,080	N/A	\$0
COVID-19 SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	COVID-19	UNIVERSITY OF WISCONSIN SYSTEM	607		\$84,317	\$1,106,080	N/A	\$0
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD007582	FLORIDA A&M UNIVERSITY	MD007582		\$15,906	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD013490			\$15,476	\$292,459	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD08934			\$19,150	\$137,094	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD09682			\$23,806	\$305,025	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD10728	MEDICAL COLLEGE OF WISCONSIN	MD10728		\$43,423	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MG08934				\$18,260	\$812,167	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	AI142773				\$408,469	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	CA195764				\$9,352	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	CA243545				\$22,009	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				\$885,378	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	HG09450			\$3,000	\$50,593	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	OD23121				\$14,715,962	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	TR000884				\$89,881	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
TRANS-NIH RESEARCH SUPPORT	93.310	TR02471				\$585,534	\$16,767,178	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	AG58516	KORONIS BIOMEDICAL TECH CORP	AG58516		\$6,409	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002014	PENNSYLVANIA STATE UNIVERSITY	TR002014		\$3,630	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002377			\$2,086	\$6,315,313	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002379			\$2,469	\$1,541,191	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02062			\$1,240,638	\$1,955,022	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02380				\$534,668	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02494	UNIVERSITY OF MINNESOTA	TR02494		\$136,491	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02743			\$311,000	\$713,193	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR03174				\$148,122	\$11,354,039	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD20166	IOWA STATE UNIVERSITY	OD20166		\$432,420	\$465,545	RESEARCH AND DEVELOPMENT	\$380,451,621
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD25340	UNIVERSITY OF WISCONSIN-MADISON	OD25340		\$33,125	\$465,545	RESEARCH AND DEVELOPMENT	\$380,451,621
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA15083				\$203,426	\$3,321,162	RESEARCH AND DEVELOPMENT	\$380,451,621
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA224018			\$186,376	\$998,389	\$3,321,162	RESEARCH AND DEVELOPMENT	\$380,451,621
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233033			\$105,801	\$1,603,371	\$3,321,162	RESEARCH AND DEVELOPMENT	\$380,451,621
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233046	UNIVERSITY OF NORTH CAROLINA	CA233046		\$313,155	\$3,321,162	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA246568			\$69,831	\$202,821	\$3,321,162	RESEARCH AND DEVELOPMENT	\$380,451,621
NURSING RESEARCH	93.361	NR15259				\$813,217	\$1,802,939	RESEARCH AND DEVELOPMENT	\$380,451,621
NURSING RESEARCH	93.361	NR15441			\$157,617	\$344,200	\$1,802,939	RESEARCH AND DEVELOPMENT	\$380,451,621
NURSING RESEARCH	93.361	NR16433				\$637,721	\$1,802,939	RESEARCH AND DEVELOPMENT	\$380,451,621
NURSING RESEARCH	93.361	NR18832				\$7,801	\$1,802,939	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA116167				\$24,512	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA118553</i>	<i>YALE UNIVERSITY</i>	<i>CA118553</i>		<i>\$7,100</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA132878				\$54,327	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA134514				\$282,594	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA142714</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>CA142714</i>		<i>\$22,348</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA154823</i>	<i>JOHNS HOPKINS UNIVERSITY</i>	<i>CA154823</i>		<i>\$42,583</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA164533			\$89,243	\$173,143	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA167551</i>	<i>STANFORD UNIVERSITY</i>	<i>CA167551</i>		<i>\$163,061</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA179243				\$34,737	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA192393			\$61,828	\$223,598	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			\$972,522	\$1,690,549	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA200703			\$126,607	\$682,864	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA203050</i>	<i>IMBIO, LLC</i>	<i>CA203050</i>		<i>\$43,943</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA203923</i>	<i>MEDICAL COLLEGE OF WISCONSIN</i>	<i>CA203923</i>		<i>\$11,902</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA203971				\$480,560	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207084			\$401,712	\$617,486	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA207360</i>	<i>UNIVERSITY OF CALIFORNIA SAN FRANCISCO</i>	<i>CA207360</i>		<i>\$18,594</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA207369</i>	<i>UNIVERSITY OF MASSACHUSETTS</i>	<i>CA207369</i>		<i>\$136,939</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA207456</i>	<i>H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC.</i>	<i>CA207456</i>		<i>\$11,641</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA208517				\$755,195	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA213035</i>	<i>ARIZONA STATE UNIVERSITY</i>	<i>CA213035</i>		<i>\$19,263</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA213645			\$416,407	\$604,142	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217183				\$367,470	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889				\$382,283	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA222253</i>	<i>UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER</i>	<i>CA222253</i>		<i>\$27,723</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA222867			\$9,869	\$104,102	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA224293</i>	<i>UNIVERSITY OF VIRGINIA</i>	<i>CA224293</i>		<i>\$59,946</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224917				\$657,284	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662				\$375,354	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA226081</i>	<i>STANFORD UNIVERSITY</i>	<i>CA226081</i>		<i>\$15,504</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA230712				\$634,076	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233522				\$43,708	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610				\$548,758	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				\$331,758	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA234943				\$28,518	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				\$588,425	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235189				\$72,498	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237607			\$51,853	\$601,582	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA243483</i>	<i>BAYLOR COLLEGE OF MEDICINE</i>	<i>CA243483</i>		<i>\$16,170</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA247283</i>	<i>JOHNS HOPKINS UNIVERSITY</i>	<i>CA247283</i>		<i>\$145</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER CAUSE AND PREVENTION RESEARCH</i>	<i>93.393</i>	<i>CA247642</i>	<i>ALASKA NATIVE TRIBAL HEALTH CONSORTIUM</i>	<i>CA247642</i>		<i>\$1,969</i>	<i>\$11,058,116</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				\$99,762	\$11,058,116	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA107476				\$179,622	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA116161				\$239,837	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA158079</i>	<i>ST. JOSEPH HOSPITAL</i>	<i>CA158079</i>		<i>\$91,088</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA161749</i>	<i>UNIVERSITY OF PENNSYLVANIA</i>	<i>CA161749</i>		<i>\$142,565</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168575				\$27,535	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168762				\$112,183	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA174723				\$27,487	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA177734				\$41,889	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA184102</i>	<i>PARTNERS HEALTH CARE RES MGMT</i>	<i>CA184102</i>		<i>\$17,688</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA187112				\$84,582	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193541			\$32,475	\$279,952	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195527			\$219,933	\$354,314	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195688				\$375,583	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA196171</i>	<i>WASHINGTON UNIVERSITY IN ST. LOUIS</i>	<i>CA196171</i>		<i>\$445,488</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA196172</i>	<i>COALITION OF NTL CANCER COOP</i>	<i>CA196172</i>		<i>\$4,541</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA197120			\$12,731	\$534,379	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA197488</i>	<i>UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN</i>	<i>CA197488</i>		<i>\$81,250</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA199948</i>	<i>ARIZONA STATE UNIVERSITY</i>	<i>CA199948</i>		<i>\$10,589</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CANCER DETECTION AND DIAGNOSIS RESEARCH</i>	<i>93.394</i>	<i>CA199996</i>	<i>UNIVERSITY OF WISCONSIN</i>	<i>CA199996</i>		<i>\$29,816</i>	<i>\$11,581,758</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA200399	JOHNS HOPKINS UNIVERSITY	CA200399		\$371,074	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA204013				\$789,585	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA206584			\$254,401	\$543,998	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210138			\$213,776	\$1,203,560	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210509			\$133,773	\$460,948	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA212162			\$36,397	\$623,790	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA213158	ST. JOSEPH HOSPITAL	CA213158		\$27,613	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214114	FRED HUTCHINSON CANCER RESEARCH CENTER	CA214114		\$69,521	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214125	BAYLOR RESEARCH INSTITUTE	CA214125		\$9,340	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214679				\$480,928	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA216066	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	CA216066		\$9,688	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA216855			\$161,828	\$609,251	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA217847				\$361,705	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA218429	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	CA218429		\$83,061	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA221490	CELL REPROGRAMMING & THERAPEUTICS LLC	CA221490		\$38,101	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA221938	ST. JOSEPH HOSPITAL	CA221938		\$66,171	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA223426	UNIVERSITY OF CHICAGO	CA223426		\$122,742	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA223481	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	CA223481		\$26,402	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229811			\$7,270	\$684,518	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA234827				\$207,805	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA236612				\$119,099	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237602				\$100,031	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237659	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	CA237659		\$113,433	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA238926				\$195,344	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				\$237,552	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200				\$31,216	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				\$535,746	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA240181	PURDUE UNIVERSITY	CA240181		\$13,136	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164				\$261,296	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA244167				\$39,376	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246704	UNIVERSITY OF CENTRAL FLORIDA	CA246704		\$16,861	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251923				\$44,388	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA252156	MD ANDERSON CANCER CENTER	CA252156		\$4,091	\$11,581,758	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA108671	MOUNT SINAI MEDICAL CENTER OF FLORIDA	CA108671		\$441,447	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA150190			\$203,694	\$474,397	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA174779			\$18,379	\$46,929	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA179157				\$173,930	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180709	DANA-FARBER CANCER INSTITUTE	CA180709		\$13,866	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180820	COALITION OF NTL CANCER COOP	CA180820		\$34,924	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180821	BRIGHAM AND WOMEN'S HOSPITAL	CA180821		\$275,614	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180868	NRG ONCOLOGY FOUNDATION	CA180868		\$1,897	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180882			\$1,286,702	\$8,098,918	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180886	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	CA180886		\$24,074	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA180888	OREGON HEALTH SCIENCES UNIVERSITY	CA180888		\$4,751	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA181255	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA181255		\$289,344	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA182901	ARIZONA STATE UNIVERSITY	CA182901		\$17,812	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA183827				\$54,070	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA184165				\$310,354	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA186686			\$4,187	\$667,533	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA186709	DANA-FARBER CANCER INSTITUTE	CA186709		\$226,105	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA189955	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	CA189955		\$1,970	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA190423			\$15,763	\$111,498	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA190473				\$234,915	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA194498				\$235,302	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA195473				\$350,860	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA195503			\$98,774	\$502,293	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA195946	MODULATION THERAPEUTICS	CA195946		\$166,361	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA196854	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	CA196854		\$883	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA198096	UNIVERSITY AT BUFFALO	CA198096		\$5,932	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA200507				\$496,101	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA200551				\$129,204	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA201226			\$149,000	\$179,952	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA203430	PPD DEVELOPMENT	CA203430		\$119,955	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA203561				\$331,614	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA203836				\$459,172	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	CA205406	DANA-FARBER CANCER INSTITUTE	CA205406		\$38,698	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA207183			\$8,192	\$188,813	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA207240				\$480,223	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA207386				\$365,802	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA21115	FRONTIER SCIENCE & TECHNOLOGY	CA21115		\$115	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA211887				\$395,689	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA215867				\$30,211	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA216436	UNIVERSITY OF CHICAGO	CA216436		\$80,871	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA216468	MD ANDERSON CANCER CENTER	CA216468		\$36,780	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA217591	SYNTRIX BIOSYSTEMS, INC.	CA217591		\$9,160	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA219960				\$487,558	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA221461	VYRIAD	CA221461		\$38,325	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA222425				\$105,763	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA222866	VETERANS MEDICAL RESEARCH FOUNDATION	CA222866		\$37,822	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA225996				\$81,373	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA226302				\$154,742	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA227954			\$176,827	\$641,108	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA228823	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	CA228823		\$11,871	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA229100			\$1,305,575	\$2,300,720	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA229560				\$435,165	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA229943	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	CA229943		\$7,416	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA232760				\$523,463	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA232761				\$191,425	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA232762				\$464,475	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA233024	VYRIAD	CA233024		\$99,253	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA233878	NORTHWESTERN UNIVERSITY	CA233878		\$68,190	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA235726	UNIVERSITY OF MICHIGAN	CA235726		\$15,202	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA238946	OHIO STATE UNIVERSITY	CA238946		\$27,195	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA242158				\$562,228	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA243078	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	CA243078		\$24,450	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA251910	SANFORD-BURNHAM MEDICAL	CA251910		\$13,126	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA25224				\$5,227	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA256927				\$6,389	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	CA37404				\$6,345	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA78383				\$45,140	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	CA84203	PARTNERS HEALTH CARE RES MGMT	CA84203		\$102,214	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	E1412	EASTERN COOPERATIVE ONCOLOGY GROUP	E1412		\$5,807	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER TREATMENT RESEARCH	93.395	GOG	THE GYNECOLOGIC ONCOLOGY GROUP	GOG		\$87	\$22,570,418	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA104125				\$157,233	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA130908				\$463,222	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA136526			\$3,971	\$207,472	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA152108	UNIVERSITY OF WISCONSIN-MADISON	CA152108		\$130,318	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA154387				\$23,434	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA172503				\$156,229	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA186338	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	CA186338		\$18,301	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA187692	PRINCETON UNIVERSITY	CA187692		\$32,703	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA193239				\$233,371	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA194215	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER	CA194215		\$95,071	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA196648				\$234,563	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA196831				\$193,538	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA200572			\$14,849	\$274,737	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA203108	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	CA203108		\$9,000	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA203849				\$400,304	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA206367				\$344,578	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA214292	BOSTON UNIVERSITY	CA214292		\$15,291	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA214893				\$325,923	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA215973	MDI BIOLOGICAL LABORATORY	CA215973		\$4,250	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA217833				\$324,226	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA220378			\$160,417	\$604,294	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA224921				\$400,339	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA225680				\$452,755	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA233790				\$827,180	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA234181				\$363,212	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA240323				\$114,576	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA241123	UNIVERSITY AT BUFFALO	CA241123		\$27,382	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA242023				\$194,073	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER BIOLOGY RESEARCH	93.396	CA243545			\$6,039	\$409,735	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA81436				\$473,538	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER BIOLOGY RESEARCH	93.396	CA96985				\$171,930	\$7,682,778	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA102701				\$346,961	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			\$145,050	\$2,231,257	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA118100	UNIVERSITY OF NEW MEXICO	CA118100		\$23,030	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393			\$449,762	\$1,592,197	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083			\$1,957	\$5,733,620	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA163004	COLUMBIA UNIVERSITY CASE WESTERN RESERVE UNIVERSITY	CA163004		\$157,058	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA163060	DANA-FARBER CANCER INSTITUTE	CA163060		\$23,628	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA168504				\$6,207	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781	H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC.	CA193489		\$1,514,251	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA193489				\$160,296	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA210180	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	CA210180		\$878,197	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA210181	METHODIST HOSPITAL RESEARCH	CA210181		\$15,387	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA210190	UNIVERSITY OF MINNESOTA	CA210190		\$147,592	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			\$546,158	\$2,633,423	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA221205	NORTHWESTERN UNIVERSITY	CA221205		\$31,766	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CENTERS SUPPORT GRANTS	93.397	CA97274	UNIVERSITY OF IOWA	CA97274	\$51,080	\$1,900,338	\$17,395,208	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA210334				\$52,693	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA213737				\$19,868	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA215105				\$151,764	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA217836				\$215,413	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA218742				\$115,346	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA220660				\$43,909	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA225786				\$207,107	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA228193				\$37,118	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA234324				\$133,717	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA235848				\$43,286	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA236874				\$196,344	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA237875				\$87,268	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA250326				\$23,100	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER RESEARCH MANPOWER	93.398	CA90628				\$721,721	\$2,048,654	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER CONTROL	93.399	CA189823	ALLIANCE NCTN FOUNDATION	CA189823	\$84	\$2,007,877	\$9,154,175	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CONTROL	93.399	CA189823			\$2,336,185	\$6,607,041	\$9,154,175	RESEARCH AND DEVELOPMENT	\$380,451,621
CANCER CONTROL	93.399	CA220242				\$539,257	\$9,154,175	RESEARCH AND DEVELOPMENT	\$380,451,621
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0012				\$487,484	\$500,098	RESEARCH AND DEVELOPMENT	\$380,451,621
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0017	CRAIG HOSPITAL	90DPTB0017		\$12,614	\$500,098	RESEARCH AND DEVELOPMENT	\$380,451,621
COVID-19 CLAIMS REIMBURSEMENT TO HEALTH CARE PROVIDERS AND FACILITIES FOR TESTING, TREATMENT, AND VACCINE ADMINISTRATION FOR THE UNINSURED	93.461	COVID-19				\$6,025,338	\$6,025,338	N/A	\$0
ACA-TRANSFORMING CLINICAL PRACTICE INITIATIVE: PRACTICE TRANSFORMATION NETWORKS (PTNS)	93.638	CMS331449				\$32,418	\$32,418	RESEARCH AND DEVELOPMENT	\$380,451,621
COVID-19 TESTING FOR RURAL HEALTH CLINICS	93.697	COVID-19				\$98,923	\$98,923	N/A	\$0
HOSPITAL PREPAREDNESS PROGRAM (HPP) EBOLA PREPAREDNESS AND RESPONSE ACTIVITIES	93.817	MDH102271	MINNESOTA DEPARTMENT OF HEALTH	MDH102271		\$207,500	\$485,898	RESEARCH AND DEVELOPMENT	\$380,451,621
HOSPITAL PREPAREDNESS PROGRAM (HPP) EBOLA PREPAREDNESS AND RESPONSE ACTIVITIES	93.817	MDH104013	MINNESOTA DEPARTMENT OF HEALTH	MDH104013		\$238,789	\$485,898	RESEARCH AND DEVELOPMENT	\$380,451,621
HOSPITAL PREPAREDNESS PROGRAM (HPP) EBOLA PREPAREDNESS AND RESPONSE ACTIVITIES	93.817	U3REP150527				\$39,609	\$485,898	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				\$73,776	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL105907	NEW YORK SCHOOL OF MEDICINE	HL105907		\$16,285	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304				\$215,731	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107407	NEW ENGLAND RESEARCH INSTITUTE	HL107407		\$239	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL110262				\$1,838	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL111437	UNIVERSITY OF CALIFORNIA LOS ANGELES	HL111437		\$92,994	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117006	ICON CLINICAL RESEARCH	HL117006		\$10,721	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117823			\$23,539	\$454,138	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117905	NEW YORK SCHOOL OF MEDICINE	HL117905		\$1,575	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL119795			\$22,140	\$517,038	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120877	OKLAHOMA MEDICAL RESEARCH FOUNDATION	HL120877		\$177,230	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL121079				\$160,216	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL124045				\$24,684	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL125918	YALE UNIVERSITY	HL125918		\$2,431	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL126638				\$362,648	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128526				\$382,848	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128606			\$373,631	\$960,458	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128785	ARIZONA STATE UNIVERSITY	HL128785		\$28,522	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128859				\$143,592	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL130163	BRIGHAM AND WOMEN'S HOSPITAL	HL130163		\$152	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL131515				\$63,617	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL131535			\$140,847	\$330,206	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132746	THERMEDICAL, INC.	HL132746		\$138,820	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132854				\$374,309	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501			\$172,400	\$326,594	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134664				\$220,455	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134668				\$276,246	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				\$275,301	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134905	UNIVERSITY OF PENNSYLVANIA	HL134905		\$55,116	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135165	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	HL135165		\$40,543	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135288				\$145,773	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135879				\$593,224	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135889	CALADRIUS BIOSCIENCES	HL135889		\$20,885	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136340				\$660,497	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				\$722,415	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136440				\$476,514	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136659				\$839,196	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136679	UNIVERSITY OF MINNESOTA	HL136679		\$784	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137010				\$97,055	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140205				\$3,864	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140411			\$5,015	\$443,468	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140669	VOLUMETRIX LLC	HL140669		\$63,617	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140951			\$117,268	\$491,696	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141448				\$206,555	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141819				\$351,358	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627			\$18,272	\$573,345	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL143070	MASSACHUSETTS GENERAL HOSPITAL	HL143070		\$45,367	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529				\$423,036	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			\$186,888	\$555,423	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146127	UNIVERSITY OF CHICAGO	HL146127		\$18,914	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147155				\$673,970	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148120	VERSITI	HL148120		\$14,077	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				\$118,987	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148664	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	HL148664		\$177,193	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149131				\$22,993	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149137	UNIVERSITY OF ALABAMA	HL149137		\$13,778	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151079	NORTHWESTERN UNIVERSITY	HL151079		\$8,147	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152873	MARBLEHEAD MEDICAL, LLC	HL152873		\$53,160	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155040				\$159	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL36634				\$203,887	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL66216				\$412,514	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL74180				\$256,109	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753				\$240,634	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				\$137,020	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84904	DUKE CLINICAL RESEARCH INSTITUTE	HL84904		\$59,485	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL88942	ICAHN SCHOOL OF MEDICINE	HL88942		\$1,063	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL92621				\$3,024	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812	JOHNS HOPKINS UNIVERSITY	HL96812		\$105,171	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				\$696,902	\$15,659,582	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL102033	UNIVERSITY OF FLORIDA	HL102033		\$10,928	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL105355				\$491,686	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL108800	VANDERBILT UNIVERSITY	HL108800		\$33,263	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL123494	NORTH DAKOTA STATE UNIVERSITY	HL123494		\$36,699	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL125119	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	HL125119		\$57,413	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL125177	CLEVELAND CLINIC FOUNDATION	HL125177		\$8,885	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL125205				\$61,534	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL125234				\$128,861	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL126647				\$78,709	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL126667			\$57,230	\$799,404	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL128954	UNIVERSITY OF PITTSBURGH	HL128954		\$4,715	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL130881			\$21,149	\$334,242	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL133320				\$133,880	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL134015	UNIVERSITY OF PENNSYLVANIA	HL134015		\$10,921	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL137366	PARTNERS HEALTH CARE RES MGMT	HL137366		\$111,213	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL138150			\$1,010	\$104,004	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL138402	CASE WESTERN RESERVE UNIVERSITY	HL138402		\$142,191	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL138998	UNIVERSITY OF NORTH CAROLINA	HL138998		\$4,213	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL139054	UNIVERSITY OF ARIZONA	HL139054		\$11,021	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	HL140177	MASSACHUSETTS GENERAL HOSPITAL	HL140177		\$11,991	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL140287				\$119,662	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL140486			\$156,223	\$644,282	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL141722	STANFORD UNIVERSITY	HL141722		\$252,701	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL142061				\$502,837	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL142093	BRIGHAM AND WOMEN'S HOSPITAL	HL142093		\$123,641	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL142269	UNIVERSITY OF PENNSYLVANIA	HL142269		\$108,118	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL142596	BOSTON UNIVERSITY	HL142596		\$69,017	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL142933			\$81,801	\$504,374	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL144427				\$22,547	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL146114				\$525,101	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL146705	NORTH DAKOTA STATE UNIVERSITY	HL146705		\$69,606	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL146741				\$110,605	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL147261	UNIVERSITY OF MICHIGAN	HL147261		\$2,400	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL150086				\$94,093	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL151461	MINNESOTA HEALTHSOLUTIONS CORPORATION	HL151461		\$4,081	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL153026				\$71,892	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL56470			\$154,942	\$379,091	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL62150				\$334,520	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL88029				\$681,212	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
LUNG DISEASES RESEARCH	93.838	HL92961			\$55,840	\$597,865	\$7,793,418	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1506	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1506		\$32,001	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL112792	NORTHWESTERN UNIVERSITY	HL112792		\$3,044	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL121232			\$138,032	\$165,883	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL126589	FRED HUTCHINSON CANCER RESEARCH CENTER	HL126589		\$18,149	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL129472	SLOAN-KETTERING INSTITUTE	HL129472		\$1,031	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133479				\$173,618	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133815	UNIVERSITY OF PITTSBURGH	HL133815		\$2,561	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133817	DUKE CLINICAL RESEARCH INSTITUTE	HL133817		\$8,994	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL137193			\$103,447	\$466,657	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138645	UNIVERSITY OF ALABAMA	HL138645		\$12,787	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL139854				\$713,869	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	CLEVELAND CLINIC FOUNDATION	HL140097		\$34,225	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				\$213,476	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BLOOD DISEASES AND RESOURCES RESEARCH</i>	<i>93.839</i>	<i>HL143541</i>	<i>SUBC, INC.</i>	<i>HL143541</i>		<i>\$23,665</i>	<i>\$2,365,788</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL146508				\$200,236	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				\$271,155	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154320				\$17,884	\$2,365,788	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BLOOD DISEASES AND RESOURCES RESEARCH</i>	<i>93.839</i>	<i>HL154385</i>	<i>UNIVERSITY OF WASHINGTON</i>	<i>HL154385</i>		<i>\$6,553</i>	<i>\$2,365,788</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662			\$13,380	\$177,651	\$177,651	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR27065			\$24,784	\$672,080	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR46849				\$687,224	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR49069				\$359,078	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55563			\$140,404	\$441,391	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				\$306,734	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56647				\$515,317	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56950				\$415,532	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH</i>	<i>93.846</i>	<i>AR57319</i>	<i>UNIVERSITY OF PENNSYLVANIA</i>	<i>AR57319</i>		<i>\$5,288</i>	<i>\$8,821,256</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR57745				\$95,849	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR62613				\$171,375	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR65402				\$187,083	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR66696				\$94,328	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR67129				\$268,326	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR67707				\$257,347	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR68103			\$57,955	\$454,816	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR68275				\$235,594	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR69850				\$48,508	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR70241				\$128,994	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71338			\$57,018	\$557,273	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH</i>	<i>93.846</i>	<i>AR71439</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>AR71439</i>		<i>\$14,890</i>	<i>\$8,821,256</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH</i>	<i>93.846</i>	<i>AR72222</i>	<i>ICAHN SCHOOL OF MEDICINE</i>	<i>AR72222</i>		<i>\$12,251</i>	<i>\$8,821,256</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72597				\$295,056	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH</i>	<i>93.846</i>	<i>AR72634</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>AR72634</i>		<i>\$38,501</i>	<i>\$8,821,256</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147			\$165,394	\$671,116	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73811				\$306,487	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74228				\$147,493	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395				\$445,117	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74523	NORTHWESTERN UNIVERSITY	AR74523		\$37,943	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				\$365,644	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75370				\$119,465	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75803	UNIVERSITY OF NORTH CAROLINA	AR75803		\$134,293	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			\$104,950	\$321,381	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76568	UNIVERSITY OF PITTSBURGH	AR76568		\$9,482	\$8,821,256	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	APOL1	UNIVERSITY OF MIAMI	APOL1		\$520	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK067071				\$534,656	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				\$181,408	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				\$247,948	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				\$347,924	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK078646			\$24,891	\$611,521	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100846	UNIVERSITY OF PENNSYLVANIA	DK100846		\$5,290	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	DK100866		\$2,179	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101402	UNIVERSITY OF MINNESOTA	DK101402		\$109,765	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				\$23,447	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103225	UNIVERSITY OF PENNSYLVANIA	DK103225		\$36,630	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103911				\$109,858	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104273				\$6,073	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104500	RECOMBINETICS, INC.	DK104500		\$121,171	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104764	UNIVERSITY OF WASHINGTON	DK104764		\$16,202	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104833	MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK104833		\$56,798	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104876	NORTHWESTERN UNIVERSITY	DK104876		\$133,346	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106130	UNIVERSITY OF MINNESOTA	DK106130		\$14,994	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106427				\$100,936	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106456				\$109,639	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106667			\$5,617	\$141,157	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106957				\$77,662	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107255				\$200,487	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107733	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	DK107733		\$181,582	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107870				\$98,632	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288	UNIVERSITY OF TEXAS	DK108288		\$11,575	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				\$422,629	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	DK108328		\$48,662	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108483	UNIVERSITY OF VIRGINIA	DK108483		\$35,916	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108743	SANFORD-BURNHAM MEDICAL	DK108743		\$5,331	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109006				\$149,811	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109096				\$166,229	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109134				\$115,674	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110024			\$205,686	\$518,624	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110096	TEXAS BIOMEDICAL RESEARCH INSTITUTE	DK110096		\$28,681	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110136				\$118,065	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110172	NORTHWESTERN UNIVERSITY	DK110172		\$216,260	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110988	DUKE UNIVERSITY	DK110988		\$249,994	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111024	EMORY UNIVERSITY	DK111024		\$13,773	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				\$373,643	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111397				\$20,294	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111630			\$405	\$405	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112915				\$173,078	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113111	UNIVERSITY OF KANSAS MEDICAL CENTER	DK113111		\$179,653	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113339				\$39,155	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113999			\$259,999	\$397,729	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				\$297,527	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114460				\$291,707	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114497				\$169,940	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115255	GEORGIA REGENTS UNIVERSITY	DK115255		\$129,534	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115402			\$222,368	\$354,457	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575	UNIVERSITY OF NORTH CAROLINA	DK115575		\$346,399	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115594				\$186,241	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115950				\$390,868	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116102	JOSLIN DIABETES CENTER	DK116102		\$329	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231			\$56,013	\$514,507	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116610	RTC ELECTRONICS, INC.	DK116610		\$2,387	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116743	MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK116743		\$10,737	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116963	INDIANA UNIVERSITY	DK116963		\$42,772	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117133	SANFORD-BURNHAM MEDICAL	DK117133		\$253,665	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117212			\$11,235	\$61,238	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117236	MASSACHUSETTS GENERAL HOSPITAL	DK117236		\$14,074	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				\$342,277	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				\$281,806	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118120				\$143,537	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118358	ARIZONA STATE UNIVERSITY	DK118358		\$89,352	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118391				\$164,591	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619			\$784,627	\$1,790,749	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119167				\$461,009	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119646				\$564,413	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119683				\$99,289	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120292				\$631,741	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120358	HARVARD UNIVERSITY	DK120358		\$161,424	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				\$369,373	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120745				\$109,509	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120808				\$165,703	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121240	JAEB CENTER FOR HEALTH RESEARCH	DK121240		\$318	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121330	UNIVERSITY OF TEXAS-HOUSTON	DK121330		\$68,707	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121766				\$170,675	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121888				\$189,975	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121943				\$10,605	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122137				\$90,684	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122187				\$39,152	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122280				\$416,816	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122603	JAEB CENTER FOR HEALTH RESEARCH	DK122603		\$79,165	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				\$246,252	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				\$246,212	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123313				\$154,805	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123492				\$116,089	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				\$309,257	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123834				\$41,036	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123858				\$38,953	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				\$208,731	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$49,009	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				\$104,947	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252			\$4,992	\$63,732	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK125431</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>DK125431</i>		<i>\$120,501</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125632				\$27,519	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206				\$95,104	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK126607</i>	<i>SONOVOL, INC.</i>	<i>DK126607</i>		<i>\$14,999</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				\$44,063	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691				\$4,980	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126700				\$11,676	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK24031				\$87,230	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK29953</i>	<i>UNIVERSITY OF VIRGINIA</i>	<i>DK29953</i>		<i>\$32,490</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				\$535,456	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK41876				\$243,784	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				\$390,827	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44863				\$36,380	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				\$402,125	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK47060				\$69,784	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766				\$360,176	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				\$385,045	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				\$294,448	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58185			\$10,838	\$309,361	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				\$486,960	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				\$441,824	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				\$524,502	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK68055			\$8,272	\$1,096,451	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK74008</i>	<i>JOHNS HOPKINS UNIVERSITY</i>	<i>DK74008</i>		<i>\$412,139</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				\$215,862	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK82864</i>	<i>UNIVERSITY OF PITTSBURGH</i>	<i>DK82864</i>		<i>\$1,359</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK83908				\$118,230	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH</i>	<i>93.847</i>	<i>DK83912</i>	<i>UNIVERSITY OF MICHIGAN</i>	<i>DK83912</i>		<i>\$12,091</i>	<i>\$29,318,774</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84097				\$244,374	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				\$1,200,331	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK85516	UNIVERSITY OF VIRGINIA	DK85516		\$297,831	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK88925	UNIVERSITY OF WISCONSIN-MADISON	DK88925		\$48,689	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358			\$16,313	\$554,361	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90728			\$91,480	\$616,335	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90868	UNIVERSITY OF MARYLAND	DK90868		\$25,000	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255			\$81,250	\$630,656	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92460				\$50,231	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK94157	CASE WESTERN RESERVE UNIVERSITY	DK94157		\$85,288	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98203	UNIVERSITY OF MINNESOTA	DK98203		\$832	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468				\$487,877	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				\$420,155	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	MAYO-UOOFM #203	UNIVERSITY OF MINNESOTA	MAYO-UOOFM #203		\$40,167	\$29,318,774	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS062835	UNIVERSITY OF TEXAS AT AUSTIN	NS062835		\$26,189	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS063964	UNIVERSITY OF COLORADO	NS063964		\$52,298	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS085070				\$403,945	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS095869	UNIVERSITY OF CINCINNATI	NS095869		\$22,734	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				\$1,144,024	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100693			\$643,355	\$1,524,101	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100699	UNIVERSITY OF CINCINNATI	NS100699		\$23,840	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS101721				\$247,421	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102233	TUFTS MEDICAL CENTER, INC.	NS102233		\$68,773	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102289	UNIVERSITY OF CINCINNATI	NS102289		\$7,516	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102360				\$331,918	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212			\$3,000	\$670,141	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103670	MARBLEHEAD MEDICAL, LLC	NS103670		\$148,711	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103870			\$20,870	\$280,632	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104095	UNIVERSITY OF SOUTHERN CALIFORNIA	NS104095		\$108,085	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104157	UNIVERSITY OF CHICAGO	NS104157		\$68,395	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105853				\$379,924	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105894	JOHNS HOPKINS UNIVERSITY	NS105894		\$13,529	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS106513	UNIVERSITY OF CINCINNATI	NS106513		\$15,325	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107048	NEUROGAMI MEDICAL, INC.	NS107048		\$61,099	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107111	ANCURE LLC	NS107111		\$21,982	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107265				\$607,255	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107336			\$22,177	\$506,827	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107946				\$96,790	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109444				\$103,575	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109491				\$444,839	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109770				\$302,199	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109956				\$159,989	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				\$370,445	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110114	ENDOMIMETICS, LLC	NS110114		\$18,917	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			\$867,618	\$1,991,779	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110438	COLUMBIA UNIVERSITY	NS110438		\$369,852	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110728	UNIVERSITY OF CINCINNATI	NS110728		\$7,825	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110825	UNIVERSITY OF MARYLAND	NS110825		\$116,577	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110930				\$206,681	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110949				\$229,743	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110960			\$193,676	\$384,400	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110994				\$249,957	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111039	DUKE UNIVERSITY	NS111039		\$144,699	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111085	SANFORD-BURNHAM MEDICAL	NS111085		\$99,102	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111756				\$229,053	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111978	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS111978		\$43,448	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111981	CLEVELAND CLINIC FOUNDATION	NS111981		\$19,152	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144			\$23,743	\$882,296	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112176			\$65,362	\$427,543	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112339				\$116,772	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112611				\$58,405	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112826	YALE UNIVERSITY	NS112826		\$248,355	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113315			\$148,312	\$554,777	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113637	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS113637		\$2,313	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113724	EVOGEN, INC.	NS113724		\$67,798	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				\$240,978	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				\$182,842	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113828				\$359,231	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114040				\$68,310	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114117				\$77,358	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114365				\$15,281	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				\$194,478	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198			\$586,622	\$1,651,446	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115202				\$35,095	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115358				\$41,330	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115388	MASSACHUSETTS GENERAL HOSPITAL	NS115388	\$9,300	\$599,305	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115708	UNIVERSITY OF PITTSBURGH	NS115708		\$8,389	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877				\$218,358	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS116924				\$16,716	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432				\$18,884	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			\$3,314	\$125,946	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118790				\$74,671	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120348				\$107,251	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744			\$42,528	\$306,015	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS52741				\$203,689	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS65705	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS65705		\$1,572	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS65736	VANDERBILT UNIVERSITY	NS65736		\$7,608	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS73610			\$250,890	\$456,055	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS74576	NEUROSIGME INC.	NS74576		\$19,225	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS74969	WASHINGTON UNIVERSITY IN ST. LOUIS	NS74969		\$349,915	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			\$126,073	\$486,125	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS78059	WASHINGTON UNIVERSITY	NS78059		\$707	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			\$4,903,965	\$7,598,446	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80223	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	NS80223		\$47,887	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80816	UNIVERSITY OF MINNESOTA	NS80816		\$70,882	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			\$318,999	\$696,486	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84975			-\$549	\$4,966	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS86853				\$97,528	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS86905	MASSACHUSETTS GENERAL HOSPITAL	NS86905		\$876	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88260				\$162,168	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88627				\$415,717	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89692	TEXAS A&M UNIVERSITY	NS89692		\$4,839	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				\$288,012	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92091	UNIVERSITY OF MIAMI	NS92091		\$59,361	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				\$121,142	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92882			\$48,131	\$449,337	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92891				\$189,763	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92940			\$49,403	\$96,373	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92955				\$1,832	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS93334	BOSTON UNIVERSITY	NS93334	\$91,298	\$161,174	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS94124			\$128,293	\$177,746	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS94137				\$196,148	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS94399	UNIVERSITY OF MICHIGAN	NS94399		\$32,453	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495			\$121,354	\$203,032	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95869	UNIVERSITY OF CINCINNATI	NS95869		\$13,932	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS96761	UNIVERSITY OF MINNESOTA	NS96761		\$138,190	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				\$1,696,914	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97495				\$159,737	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97719	CLEVELAND CLINIC FOUNDATION	NS97719		\$121,213	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97876	COLUMBIA UNIVERSITY	NS97876	\$151,678	\$291,716	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS98862	STELLENBOSCH UNIVERSITY	NS98862		\$6,839	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	UNIVERSITY OF CINCINNATI	NS99043		\$37,353	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99114	SCRIPPS RESEARCH INSTITUTE	NS99114		\$353,457	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99268	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS99268		\$7,427	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99631				\$70,360	\$34,522,031	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A107425				\$211,858	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1104681	DUKE UNIVERSITY	A1104681		\$266,595	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1105066				\$119,016	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108682	UNIVERSITY OF CHICAGO	A1108682		\$3,251	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1109565	BENAROYA RESEARCH INSTITUTE	A1109565		\$14,890	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1110173				\$591,436	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1110483	EMORY UNIVERSITY	A1110483		\$40,454	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI112844	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	AI113362	\$12,120	\$276,464	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI113362			\$81,191	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116501	WASHINGTON UNIVERSITY	AI116501		\$5,475	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120698				\$430,413	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120959				\$325,686	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121054			\$547,005	\$679,718	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122369	UNIVERSITY OF PITTSBURGH	AI122369		\$143,066	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122742	UNIVERSITY OF MINNESOTA	AI122742		\$43,365	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125053	UNIVERSITY OF WISCONSIN-MADISON	AI125053		\$71,781	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127365				\$317,105	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI128729			\$269,753	\$657,590	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI131011				\$18,372	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI131566	EMORY UNIVERSITY	AI131566		\$183,260	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				\$127,618	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132348				\$483,635	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132402	UNIVERSITY OF IOWA	AI132402		\$62,079	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132405	ICAHN SCHOOL OF MEDICINE	AI132405		\$289,420	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132840				\$77,145	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134406	UNIVERSITY OF MINNESOTA	AI134406		\$37,370	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134770	UNIVERSITY OF MASSACHUSETTS	AI134770		\$40,349	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134937				\$538,815	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135858				\$175,960	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI136718			\$406,296	\$519,255	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138965				\$1,100,585	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138993	ARIZONA STATE UNIVERSITY	AI138993		\$8,243	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI139381				\$66,446	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141591	UNIVERSITY OF MICHIGAN	AI141591		\$126,558	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141765				\$216,578	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI142702				\$138,313	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI142978	SONORAN BIOSCIENCES, INC.	AI142978		\$617	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143791			\$11,158	\$52,705	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143882				\$165,202	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144301	JOAN & SANFORD I. WEILL MEDICAL COLLEGE	AI144301		\$1,324	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144721				\$175,711	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI145108</i>	<i>UNIVERSITY OF VIRGINIA</i>	<i>AI145108</i>		<i>\$117,016</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145356			\$158,249	\$301,148	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145407				\$237,679	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146431			\$30,661	\$104,262	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI146644</i>	<i>SCRIPPS RESEARCH INSTITUTE</i>	<i>AI146644</i>		<i>\$11,088</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147368				\$4,242	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147394				\$491,040	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147438				\$12,509	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147671			\$8,000	\$8,000	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI148963</i>	<i>ICAHN SCHOOL OF MEDICINE</i>	<i>AI148963</i>		<i>\$4,369</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150100				\$176,072	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150599				\$131,937	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150649				\$115,760	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151208				\$52,924	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152318				\$177,176	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154598				\$208,537	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154927				\$25,267	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI21747</i>	<i>UNIVERSITY OF CONNECTICUT</i>	<i>AI21747</i>		<i>\$48,189</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI33144				\$702,308	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI48793				\$221,540	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI52417				\$443,947	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI68641</i>	<i>INSTITUTE FOR CLINICAL RESEARCH</i>	<i>AI68641</i>		<i>\$62,476</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI71106				\$532,634	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI83279				\$98,137	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI89714				\$403,457	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI91594			\$213,467	\$359,601	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>ALLERGY AND INFECTIOUS DISEASES RESEARCH</i>	<i>93.855</i>	<i>AI95542</i>	<i>WASHINGTON UNIVERSITY</i>	<i>AI95542</i>		<i>\$30,339</i>	<i>\$13,967,723</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI96326				\$1,155	\$13,967,723	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063904			\$179,704	\$400,678	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM075148				\$35,954	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				\$457,682	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BIOMEDICAL RESEARCH AND RESEARCH TRAINING</i>	<i>93.859</i>	<i>GM105688</i>	<i>CORNELL COLLEGE-VET MEDICINE</i>	<i>GM105688</i>		<i>\$110,442</i>	<i>\$8,218,822</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM116829				\$246,846	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>BIOMEDICAL RESEARCH AND RESEARCH TRAINING</i>	<i>93.859</i>	<i>GM118079</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>GM118079</i>		<i>\$31,723</i>	<i>\$8,218,822</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>BIOMEDICAL RESEARCH AND RESEARCH TRAINING</i>	<i>93.859</i>	<i>GM120079</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>GM120079</i>		<i>\$130,594</i>	<i>\$8,218,822</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM123757			\$340,880	\$509,620	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM125633				\$294,955	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM126086			\$182,583	\$749,717	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128253			\$49,261	\$337,577	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128579				\$375,360	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128594				\$523,041	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130556			\$495,589	\$574,889	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130588				\$719	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132095			\$89,851	\$386,637	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				\$194,617	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM134732				\$316,547	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				\$52,561	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				\$186,200	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM138636				\$13,237	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM28157			\$8,317	\$224,812	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				\$472,167	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65450				\$281,187	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65841				\$547,103	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM72474				\$172,500	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75148				\$307,282	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75965			\$62,712	\$62,712	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	OD21879			\$49,952	\$221,463	\$8,218,822	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>	<i>HD100251</i>	<i>SERSENSE, INC.</i>	<i>HD100251</i>		<i>\$81,457</i>	<i>\$1,515,439</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>	<i>HD44763</i>	<i>UNIVERSITY OF MINNESOTA</i>	<i>HD44763</i>		<i>\$100,448</i>	<i>\$1,515,439</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD65987				\$536,936	\$1,515,439	RESEARCH AND DEVELOPMENT	\$380,451,621
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD79439			\$191,637	\$264,810	\$1,515,439	RESEARCH AND DEVELOPMENT	\$380,451,621
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423			\$21,476	\$273,806	\$1,515,439	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>	<i>HD86843</i>	<i>UNIVERSITY OF PITTSBURGH</i>	<i>HD86843</i>		<i>\$29,837</i>	<i>\$1,515,439</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>	<i>HD87213</i>	<i>USF MORISANI COLLEGE OF MEDICINE</i>	<i>HD87213</i>		<i>\$21,066</i>	<i>\$1,515,439</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>	<i>HD87413</i>	<i>UNIVERSITY OF VIRGINIA</i>	<i>HD87413</i>		<i>\$1,206</i>	<i>\$1,515,439</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD91337				\$19,552	\$1,515,439	RESEARCH AND DEVELOPMENT	\$380,451,621
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147				\$186,321	\$1,515,439	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG03949	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	AG03949		\$112,561	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG046205				\$762,584	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG04875				\$906,640	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG054014	ICAHN SCHOOL OF MEDICINE	AG054014		\$72,498	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG054517	WASHINGTON UNIVERSITY	AG054517		\$6,370	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG055104	THE JACKSON LABORATORY UNIVERSITY OF SOUTHERN CALIFORNIA	AG055104		\$82,677	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG057437				\$11,238	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG058699			\$12,389	\$12,389	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG058812				\$6,427	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG061359	DUKE UNIVERSITY	AG061359		\$30,617	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG061796				\$1,795,280	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG062110				\$385,822	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG062348	BOSTON UNIVERSITY	AG062348	\$10,852	\$69,091	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG067593				\$1,006,035	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG06786				\$3,413,124	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG11378				\$700,203	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG13925			\$63,695	\$289,892	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG16574				\$6,362	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG167418	UCB PHARMA, INC.	AG167418		\$69,191	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG16976	UNIVERSITY OF WASHINGTON SUN HEALTH RESEARCH INSTITUTE	AG16976		\$6,568	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG19610	UNIVERSITY OF SOUTHERN CALIFORNIA	AG19610		\$204,315	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG24904				\$916,526	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG27924				\$116,874	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG32438	WASHINGTON UNIVERSITY	AG32438		\$101,155	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG34676			\$38,312	\$385,184	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG35355				\$166,528	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG37491				\$367,852	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG38791	UNIVERSITY OF SOUTHERN CALIFORNIA	AG38791		\$74,772	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG39449	BRIGHAM AND WOMEN'S HOSPITAL	AG39449		\$2,954	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG40282	JOHNS HOPKINS UNIVERSITY	AG40282		\$11,491	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG41676				\$7,585	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG41851				\$646,854	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG43392	UNIVERSITY OF MINNESOTA	AG43392		\$9,664	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG44170				\$1,601,511	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG44615				\$682,923	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG45390			\$306,877	\$306,877	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG45703	GEORGIA INSTITUTE OF TECHNOLOGY	AG45703		\$10,880	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG46139	UNIVERSITY OF FLORIDA	AG46139		\$845,858	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG46139				\$532,078	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG46205				\$31,981	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG47156				\$122,843	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG48792				\$48,989	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG49672				\$167,737	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG49704				\$208,825	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG49810	UNIVERSITY OF CALIFORNIA SAN DIEGO	AG49810		\$77,199	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG50603				\$381,721	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG51406	UNIVERSITY OF PITTSBURGH	AG51406		\$45,444	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG51504			\$342,574	\$1,599,215	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG51550	DUKE UNIVERSITY	AG51550		\$50,000	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG51574	NORTH DAKOTA STATE UNIVERSITY	AG51574		\$264,288	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG51679				\$173,260	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG52350	UNIVERSITY OF SOUTHERN CALIFORNIA	AG52350		\$33,014	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG52425			-\$11,022	\$433,732	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG52822				\$15,069	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG52943	UNIVERSITY OF PENNSYLVANIA	AG52943		\$111,970	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG53229				\$483,414	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG53267	WASHINGTON UNIVERSITY	AG53267		\$41,381	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG53798	UNIVERSITY OF SOUTHERN CALIFORNIA	AG53798		\$24,222	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG53832			\$45,467	\$327,794	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54029	MASSACHUSETTS GENERAL HOSPITAL	AG54029		\$249,557	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54048	ARIZONA STATE UNIVERSITY	AG54048		\$16,876	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54256	ADVANCED BRAIN MONITORING, INC.	AG54256		\$159	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54449				\$675,742	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54454				\$564,048	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG54787	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	AG54787		\$67,014	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG54890				\$22,403	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55121	NORTHWESTERN UNIVERSITY	AG55121		\$24,626	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55151				\$777,433	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55152	INNOVATIVE DESIGN LABS INC.	AG55152		\$78,854	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55444	BANNER ALZHEIMER'S INSTITUTE	AG55444		\$20,899	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55469	UNIVERSITY OF MINNESOTA	AG55469		\$23,772	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55529			\$73,679	\$769,617	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55549				\$734,203	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG55606	WAKE FOREST	AG55606		\$11,131	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56130	SANFORD-BURNHAM MEDICAL	AG56130		\$329,695	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56255			\$287,389	\$725,220	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56270	COLUMBIA UNIVERSITY	AG56270		\$125,917	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56315			\$279,981	\$502,021	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56318	BOSTON UNIVERSITY	AG56318		\$234,613	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56366			\$94,801	\$840,451	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56639	WASHINGTON UNIVERSITY	AG56639		\$109,333	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG56933	JOHNS HOPKINS UNIVERSITY	AG56933		\$9,366	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57015				\$205,968	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57052				\$393,832	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57181			\$18,466	\$824,095	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57195	INDIANA UNIVERSITY	AG57195		\$578,127	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57437	UNIVERSITY OF SOUTHERN CALIFORNIA	AG57437		\$651,997	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57441	NORTHWESTERN UNIVERSITY	AG57441		\$48,583	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57493				\$286,943	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57531	UNIVERSITY OF NEW SOUTH WALES	AG57531		\$18,696	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57547			\$1,332,699	\$2,120,276	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57708				\$3,373	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57981				\$5,877	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG57997				\$8,248	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58266			\$63,851	\$353,660	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58269	XYKEN, LLC	AG58269		\$3,173	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58560				\$442,178	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG58676	UNIVERSITY OF MELBOURNE	AG58676		\$24,806	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58729	HENNEPIN HEALTHCARE RESEARCH	AG58729		\$38,356	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58738			\$26,731	\$311,211	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58798				\$151,219	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG58812				\$480,473	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG59009	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	AG59009		\$107,517	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG59093	DUKE UNIVERSITY	AG59093		\$13,481	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG59417	DUKE UNIVERSITY	AG59417		\$8,256	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG59654	UNIVERSITY OF MINNESOTA	AG59654		\$15,186	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG59798	WASHINGTON UNIVERSITY	AG59798		\$35,959	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG60139				\$214,335	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG60502	JOHNS HOPKINS UNIVERSITY DANA-FARBER CANCER	AG60502		\$11,432	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG60626	INSTITUTE	AG60626		\$112,535	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG60907	CALIFORNIA PACIFIC MEDICAL CENTER	AG60907		\$30,773	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG60920				\$652,620	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61100	PARTNERS HEALTH CARE RES MGMT	AG61100		\$97,686	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61250				\$107,713	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61372	UNIVERSITY OF MINNESOTA	AG61372		\$12,258	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61414	UNIVERSITY OF CENTRAL FLORIDA	AG61414		\$103,117	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61427	YALE UNIVERSITY	AG61427		\$111,904	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61456			\$175,279	\$714,697	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG61848	UNIVERSITY OF SOUTHERN CALIFORNIA	AG61848		\$230,903	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62077				\$10,365	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62104				\$56,345	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62110				\$487,226	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62135	UNIVERSITY OF MINNESOTA	AG62135		\$274,457	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62171	JOHNS HOPKINS UNIVERSITY	AG62171		\$66,063	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62413			\$901,361	\$3,819,243	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62436			\$26,755	\$354,678	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62556			\$108,601	\$461,982	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62580			\$16,784	\$245,647	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62677				\$3,042,040	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62689	UNIVERSITY OF CALIFORNIA BERKELEY	AG62689		\$144,235	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG62823	ARIZONA STATE UNIVERSITY	AG62823		\$86,779	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG62859				\$552,586	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG63689	UNIVERSITY OF SOUTHERN CALIFORNIA	AG63689		\$374,018	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG63707				\$425,448	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG63780				\$13,376	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG63911	BRIGHAM AND WOMEN'S HOSPITAL	AG63911		\$23,379	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG63911			\$2,778,968	\$5,110,352	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG64029				\$123,088	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG64165	BRIGHAM AND WOMEN'S HOSPITAL	AG64165		\$20,802	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG64804				\$206,838	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65014	BIOSENSICS LLC MINNESOTA HEALTHSOLUTIONS CORPORATION	AG65014		\$146,792	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65088				\$55,313	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65126	MEDICAL CARE CORPORATION	AG65126		\$78,165	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65143				\$57,701	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65188	DUKE UNIVERSITY	AG65188		\$68,800	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65219				\$55,219	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65653				\$38,326	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65660				\$137,313	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65868				\$70,492	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG65942	ARIZONA STATE UNIVERSITY	AG65942		\$1,503	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG66134	COLUMBIA UNIVERSITY	AG66134		\$17,682	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG66395				\$553,565	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG67151	MASSACHUSETTS INSTITUTE	AG67151		\$3,436	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG67593				\$28,613	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG67631	INDIANA UNIVERSITY	AG67631		\$18,934	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68007				\$36,748	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68048				\$86,771	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68076				\$51,518	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68182				\$93,930	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68192				\$101,682	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68206				\$58,313	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68509				\$14,609	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG68581	ST. JUDE CHILDREN'S HOSPITAL	AG68581		\$40,589	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG69264				\$96,116	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG69767				\$1,453	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG72301				\$21,615	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	AG72898				\$78,898	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
AGING RESEARCH	93.866	CA242158				\$4,318	\$55,741,522	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY11751	JAEB CENTER FOR HEALTH RESEARCH	EY11751		\$324,387	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY14231	JAEB CENTER FOR HEALTH RESEARCH	EY14231		\$1,105	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY21727			\$31,914	\$349,184	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY23533	PENNSYLVANIA STATE UNIVERSITY	EY23533		\$1,307	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY24333			\$94,211	\$372,092	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY25181	WASHINGTON UNIVERSITY	EY25181		\$20,369	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY26490			\$20,323	\$66,011	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY26869	NEW YORK SCHOOL OF MEDICINE	EY26869		\$15,878	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY28803	IMACULAR REGENERATION	EY28803		\$94,904	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY30547				\$88,958	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
VISION RESEARCH	93.867	EY30819	ABBE VISION INC.	EY30819		\$16,581	\$1,350,776	RESEARCH AND DEVELOPMENT	\$380,451,621
MEDICAL LIBRARY ASSISTANCE	93.879	LM11563	UNIVERSITY OF WASHINGTON	LM11563		\$8,898	\$45,872	RESEARCH AND DEVELOPMENT	\$380,451,621
MEDICAL LIBRARY ASSISTANCE	93.879	LM11829	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER	LM11829		\$9,924	\$45,872	RESEARCH AND DEVELOPMENT	\$380,451,621
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934			\$3,470	\$25,594	\$45,872	RESEARCH AND DEVELOPMENT	\$380,451,621
MEDICAL LIBRARY ASSISTANCE	93.879	LM13501	NESTED KNOWLEDGE, INC.	LM13501		\$1,456	\$45,872	RESEARCH AND DEVELOPMENT	\$380,451,621
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HL156812	UNIVERSITY OF ARIZONA	HL156812		\$7,147	\$437,978	RESEARCH AND DEVELOPMENT	\$380,451,621
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HP29964			\$303,528	\$362,707	\$437,978	RESEARCH AND DEVELOPMENT	\$380,451,621
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HP33881				\$68,124	\$437,978	RESEARCH AND DEVELOPMENT	\$380,451,621
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	MDH10327	MINNESOTA DEPARTMENT OF HEALTH	MDH10327		\$199,751	\$630,082	N/A	\$0
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	47383				\$189,201	\$630,082	N/A	\$0
COVID-19 NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	COVID-19	WISCONSIN HOSPITAL ASSOCIATION	390969522		\$221,995	\$630,082	N/A	\$0
COVID-19 NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	COVID-19	FLORIDA HOSPITAL ASSOCIATION, INC.	6 U3REP200642-01-06		\$19,135	\$630,082	N/A	\$0
CONTRACT	93.RD	16X237	LEIDOS BIOMEDICAL RESEARCH	16X237		\$591,299	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	19RWSK0022	ICF RESOURCES, LLC	19RWSK0022		\$476	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	75A50120C00096				\$25,213,631	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	75N91019C00016	PACT & HEALTH LLC	75N91019C00016		\$17,380	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	75N91019C00035	NVIGEN, INC.	75N91019C00035		\$13,077	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	75N91019C00043	PACT & HEALTH LLC	75N91019C00043		\$11,208	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2020 - 12/31/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Subrecipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CONTRACT	93.RD	75N91020P00921				\$38,037	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>75N97019P00280</i>	<i>THE BROAD INSTITUTE, INC.</i>	<i>75N97019P00280</i>		<i>\$74,826</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	93.RD	HHS-A-290-2015-00013I				\$313,474	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	HHS-A-290-2015-00013I				\$406,472	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-261-2012-00034I</i>	<i>UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER</i>	<i>HHS-N-261-2012-00034I</i>		<i>\$3,890</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-261-2012-00035I</i>	<i>NORTHWESTERN UNIVERSITY</i>	<i>HHS-N-261-2012-00035I</i>		<i>\$15,249</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	93.RD	HHS-N-261-2012-00042I			\$369,630	\$1,133,152	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-261-2015-00029C</i>	<i>UNIVERSITY OF MASSACHUSETTS</i>	<i>HHS-N-261-2015-00029C</i>		<i>\$38,272</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	93.RD	HHS-N-261-2016-00024I				\$102,719	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	HHS-N-261-2018-00618P				\$315	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-268-2018-00005I</i>	<i>MOUNT SINAI SCHOOL OF MEDICINE AT NYU</i>	<i>HHS-N-268-2018-00005I</i>		<i>\$55,777</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-268-2018-00010I</i>	<i>UNIVERSITY OF MISSISSIPPI MEDICAL CENTER</i>	<i>HHS-N-268-2018-00010I</i>		<i>\$480</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	93.RD	HHS-N-272-2010-00025C				\$20,643	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-273-2018-00005I</i>	<i>SOCIAL & SCIENTIFIC SYSTEMS, INC.</i>	<i>HHS-N-273-2018-00005I</i>		<i>\$33,530</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-275-2010-00003I</i>	<i>DUKE UNIVERSITY</i>	<i>HHS-N-275-2010-00003I</i>		<i>\$7,004</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-N-275-2018-00003I</i>	<i>DUKE UNIVERSITY</i>	<i>HHS-N-275-2018-00003I</i>		<i>\$34,500</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
CONTRACT	93.RD	HHS-N-275-2018-00005I			\$326,518	\$564,159	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
CONTRACT	93.RD	HHS-O-100-2016-00009C				\$88,521	\$28,926,660	RESEARCH AND DEVELOPMENT	\$380,451,621
<i>CONTRACT</i>	<i>93.RD</i>	<i>HHS-P-233-2016-00031I</i>	<i>JBS INTERNATIONAL</i>	<i>HHS-P-233-2016-00031I</i>		<i>\$2,443</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>N02-CM-62212</i>	<i>THE CHILDREN'S HOSPITAL OF PHILADELPHIA</i>	<i>N02-CM-62212</i>		<i>\$19</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>PC35143</i>	<i>UNIVERSITY OF IOWA</i>	<i>PC35143</i>		<i>\$144,669</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
<i>CONTRACT</i>	<i>93.RD</i>	<i>W911QY-20-9-0012</i>	<i>JOHNS HOPKINS UNIVERSITY</i>	<i>W911QY-20-9-0012</i>		<i>\$1,438</i>	<i>\$28,926,660</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>\$380,451,621</i>
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	SURGEON GENERAL				\$321,320	\$321,320	N/A	\$0
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES						\$39,148,142	\$356,307,091		
TOTAL EXPENDITURES OF FEDERAL						\$42,217,065	\$404,554,976		

Please Note:
Italicized award lines indicate pass-through funding.

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.



Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2020

Table with 5 columns: Sponsor/CSFA Description/Project Description, CSFA Number, Contract / Grant / Subaward Number, Expenditures, Pass-Through to Subrecipients. Rows include STATE OF FLORIDA, Department of Elder Affairs, Department of Health, and Total Expenditures of State Financial Assistance.

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2020

1. Significant Accounting Policies

The accompanying schedules of expenditures of federal awards and Florida state financial assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic under programs of the federal and Florida state government for the year ended December 31, 2020. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of Mayo Clinic, they are not intended to, and do not, present the financial position, changes in net assets, or cash flows of Mayo Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for Assistance Listing No. 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured, which is reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Indirect cost rates for Mayo Clinic were based on applicable U.S. Department of Health and Human Services negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

3. Section 202 Direct Loans and Federal Direct Loans

The Supportive Housing for the Elderly, Section 202 Direct Loan (Assistance Listing No. 14.157) is considered a federal award until the outstanding balance is paid in full. At December 31, 2020, Luther Lakeside Apartments, Inc.'s outstanding balance is \$330,959 and Bloomer Lakeview, Inc.'s outstanding balance is \$273,218.

During the year, Mayo Clinic expended \$12,844,700 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loan and Parent Loan for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. Mayo Clinic assists the federal government by processing the applications and applying funds to student accounts from the federal government. Since this program is administered by the federal government, new loans made in the fiscal year ended December 31, 2020, related to Federal Direct Student Loans are considered current year federal expenditures, whereas the outstanding loan balances are not.

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Board of Trustees, Chief Executive Officer and
President, and Chief Financial Officer
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Mayo Clinic, which comprise the consolidated statement of financial position as of December 31, 2020, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated February 19, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Mayo Clinic's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Mayo Clinic's internal control. Accordingly, we do not express an opinion on the effectiveness of Mayo Clinic's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether Mayo Clinic’s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

February 19, 2021



Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*

Board of Trustees, Chief Executive Officer and President, and Chief Financial Officer
Mayo Clinic

Report on Compliance for Each Major Federal Program and State Financial Assistance Project

We have audited Mayo Clinic’s compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the requirements described in the Florida Department of Financial Services’ *State Projects Compliance Supplement* that could have a direct and material effect on each of Mayo Clinic’s major federal programs and state financial assistance projects for the year ended December 31, 2020. Mayo Clinic’s major federal programs and state financial assistance projects are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with federal and state of Florida statutes, regulations and the terms and conditions of its federal awards and state financial assistance projects applicable to its federal programs and state projects.

Auditor’s Responsibility

Our responsibility is to express an opinion on compliance for each of Mayo Clinic’s major federal programs and state financial assistance projects based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Those standards, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, require that we plan and perform the audit to obtain reasonable assurance about

whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program or state project occurred. An audit includes examining, on a test basis, evidence about Mayo Clinic's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our qualified and unmodified opinions on compliance for major federal programs and state financial assistance projects. However, our audit does not provide a legal determination of Mayo Clinic's compliance.

Basis for Qualified Opinion on Assistance Listing No. 93.461 COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured

As described in the accompanying schedule of findings and questioned costs, Mayo Clinic did not comply with requirements regarding Assistance Listing No. 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured, as described in finding number 2020-002 for A. Activities Allowed or Unallowed and E. Eligibility. Compliance with such requirements is necessary, in our opinion, for Mayo Clinic to comply with requirements applicable to that program.

Qualified Opinion on Assistance Listing No. 93.461 COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured

In our opinion, except for the noncompliance described in the Basis for Qualified Opinion paragraph, Mayo Clinic complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on Assistance Listing No. 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured, for the year ended December 31, 2020.

Unmodified Opinion on the Other Major Federal Program and on Each of the Other State Financial Assistance Projects

In our opinion, Mayo Clinic complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its other major federal program and on each of its other major state financial assistance projects that are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs for the year ended December 31, 2020.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs as Finding 2020-003 related to the

Research and Development Cluster and compliance nt M. Subrecipient Monitoring. Our opinion on the major federal program is not modified with respect to this matter.

Our audit of the major federal program identified as Assistance Listing #93.461 included certain audit procedures for the compliance requirement associated with activities allowed or unallowed that were limited to tests of compliance that reimbursements received, or expected to be received, related to health services allowed under this federal program. Our audit of compliance was not designed to test or provide assurance on the determination of whether a service was medically necessary, obtained through a legally appropriate referral, properly performed, rendered in a quality manner from a clinical perspective, adequately supervised, accurately documented and classified (i.e., that the correct medical bill code assigned represents the health service performed), or rendered and billed by non-sanctioned individuals. Performing procedures related to these matters is not within our professional expertise. Additional information on the nature of our procedures is available in the AICPA Audit and Accounting Guide, *Health Care Entities*. Our audit procedures for the compliance requirement associated with eligibility were limited to tests of compliance that services reimbursed, or expected to be reimbursed, were for individuals who received a temporary member identification number from the third-party service provider used by HRSA to identify a lack of active health care coverage.

Mayo Clinic's response to the noncompliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Mayo Clinic's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of Mayo Clinic is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Mayo Clinic's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program and state financial assistance project to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and state financial assistance project and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Mayo Clinic's internal control over compliance.

Our consideration of internal control over compliance was for the limited purpose described in the preceding paragraph and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be a material weakness and a significant deficiency.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses as follows:

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2020-002	93.461	COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured	A. Activities Allowed or Unallowed E. Eligibility
2020-003	Various	Research and Development Cluster	M. Subrecipient Monitoring
2020-004	Various	Research and Development Cluster	C. Cash Management

A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs to be a significant deficiency.

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2020-001	Various	Research and Development Cluster	A. Activities Allowed or Unallowed and B. Allowable Costs/Cost Principles

Mayo Clinic’s response to the internal control over compliance findings identified in our audit is described in the accompanying schedule of findings and questioned costs. Mayo Clinic’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.



Building a better
working world

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

March 29, 2022

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2020

Section I – Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

 Yes X **No**

Significant deficiency(ies) identified?

 Yes X **None Reported**

Noncompliance material to financial statements noted?

 Yes X **No**

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified?

 X **Yes** **No**

Significant deficiency(ies) identified?

 X **Yes** **None Reported**

Type of auditor’s report issued on compliance for major federal programs:

Unmodified – Research and Development Cluster

Qualified – COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 X **Yes** **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major federal programs:

Assistance Listing Numbers	Name of Federal Program or Cluster
Multiple 93.461	Research and Development Cluster COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured

Dollar threshold used to distinguish between Type A and Type B programs: \$ 3,000,000

Auditee qualified as low-risk auditee? X Yes No

Florida State Financial Assistance Projects

Internal control over major state financial assistance projects:

Material weakness(es) identified? Yes X No
 Significant deficiency(ies) identified? Yes X None Reported

Type of auditor’s report issued on compliance for major state financial assistance projects: Unmodified

Any audit findings disclosed that are required to be reported in accordance with Chapter 10.650, *Rules of the Auditor General of the State of Florida*? Yes X No

Identification of major state projects:

State CSFA Numbers	Name of State Project
64.078	Bankhead-Coley Cancer Research Program
64.135	Ed and Ethel Moore Alzheimer’s Disease Research Program

Dollar threshold used to distinguish between Type A and Type B programs: \$589,714

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

None identified.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section

Finding 2020-001

Identification of the federal program:

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 93.173, 93.273, 93.286, 93.307, 93.310, 93.350, 93.353, 93.393, 93.394, 93.395, 93.397, 93.398, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Condition:

The Mayo Clinic's (the Clinic) internal control over Information System (IS) Programmers internal service charges did not require that the initial request for services always be formally documented or approved by the Principal Investigator (PI) or appropriate individual with authority on the grant. In addition, for IS Programmers and the Biomedical Imaging Resource (BIR) Core, the specific grant activity number to be charged was not always documented during the intake process when the initial request for services is made.

Cause:

The Clinic's policies and procedures did not specifically require the PI or appropriate individual with authority on the grant to initiate/open the request for services. Requests could be verbal or through email and, therefore, initiated/opened by the IS programmer during the intake process. In addition, policies and procedures did not require the grant activity number to be documented during the intake process.

Effect or potential effect:

IS Programmer and BIR Core costs could be charged to the incorrect federal grant activity within the general ledger.

Questioned costs:

None.

Context:

IS Programmer and BIR Core expenditures reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$3,293,158 and \$211,186, respectively, for the year ended December 31, 2020. Total federal expenditures for the Research and Development Cluster are \$380,451,621 for the year ended December 31, 2020.

Identification as a repeat finding, if applicable:

The finding is a repeat of Finding 2019-001 in the prior year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Recommendation:

The Clinic should ensure that all R&D awards, subawards, and contracts that use IS Programmer and BIR Core services comply with the updated policies, procedures, and internal controls approved on October 1, 2020.

Views of responsible officials:

Management agrees with this finding and has corrected the finding as it relates to IS Programmers where full implementation of the corrective action plan began in fiscal year 2021. Management will work with the BIR Core to ensure requests for core services are appropriately documented.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Finding 2020-002

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: February 4, 2020 through December 31, 2020

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Health and Human Services (HHS) – Health Resources and Services and Administrative (HRSA) issued *Terms and Conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program* (T&Cs) outlining requirements that recipients of funding from the HRSA COVID-19 Uninsured Program must comply with, including the following sections: Testing Services, Treatment Services and Vaccine Administration, and General Provisions in FY2020 Consolidated Appropriations.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Per the HRSA T&Cs and further clarified in the HRSA *FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration*, the FAQ states the following:

“If a provider tests for COVID-19 as part of pre-operative or other medical treatment unrelated to COVID-19, is the test eligible for reimbursement?”

For the HRSA COVID-19 Uninsured Program, COVID-19 testing is eligible for reimbursement if one of the following diagnoses codes is included in any position on the claim:

- Z03.818 – Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19)
- Z11.59 – Encounter for screening for other viral diseases (asymptomatic)
- Z20.828 – Contact with and (suspected) exposure to other viral communicable (confirmed exposure to COVID-19)
- Z11.52 – Encounter for screening for COVID-19 (asymptomatic)
- Z20.822 – Contact with and (suspected) exposure to COVID-19
- Z86.16 – Personal history of COVID-19

Related treatment visits and services are not eligible for reimbursement given the primary reason for treatment is not COVID-19.”

Per the HRSA T&Cs (for COVID-19 testing and testing-related items):

“FFCRA Uninsured Individuals means individuals who, as of the date of service for which Recipient seeks Payment, are not enrolled in—

- A Federal health care program (as defined under section 1128B(f) of the Social Security Act (42 U.S.C. 1320a-7b(f)), including an individual who is eligible for medical assistance only because of subsection (a)(10)(A)(ii)(XXIII) of Section 1902 of the Social Security Act; or

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

- A group health plan or health insurance coverage offered by a health insurance issuer in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act (42 U.S.C. 300gg-91)), or a health plan offered under chapter 89 of title 5, United States Code.”

Per the HRSA T&Cs (for COVID-19 treatment):

Uninsured individuals are “individuals who do not have any health care coverage at the time the services were provided.”

Condition:

The Clinic did not document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

For certain emergency department and physician office visits that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, the Clinic erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Internal controls over the determination of a patient’s uninsured/self-pay status were not operating effectively. In addition, inadequate support was retained in the patient billing and recordkeeping system related to the determination of the patient’s uninsured/self-pay status and in some instances, no support was retained.

Refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

Furthermore, a risk exists that the data relevant to the HRSA COVID-19 Uninsured Program stored within the patient accounting system may be inappropriately created or modified. Evidence of the operation of controls identified to address this risk during the fiscal period under audit was not retained.

Cause:

The Clinic did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic did not have internal controls in place to monitor the Program T&Cs and underlying HRSA COVID-19 Uninsured Program regulations during the COVID-19 pandemic.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

The Clinic did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program's allowability requirements. Outpatient encounters that included a COVID-19 testing diagnosis code, with primary treatment diagnosis code not COVID-19 related, were not reviewed prior to submission to HRSA to verify treatment costs were allowable under the HRSA COVID-19 Uninsured Program.

Internal controls were not consistently performed and documented related to the determination of a patient's uninsured/self-pay status.

The Clinic did not have suitably designed controls in place to ensure that the HRSA COVID-19 Uninsured Program is reimbursed for services provided to patients that have retroactively been approved for alternate insurance coverage.

Management did not retain sufficient supporting documentation to provide evidence that controls over data integrity for this major program were designed effectively and placed in operation during the period under audit.

Effect or potential effect:

The Clinic could be in noncompliance with the HRSA COVID-19 Uninsured Program T&Cs.

Certain claims submitted to the HRSA COVID-19 Uninsured Program were for unallowable activities and were, therefore, not eligible for reimbursement under the HRSA COVID-19 Uninsured Program.

A patient may not be uninsured, and, therefore, the related encounter may be ineligible for reimbursement under the HRSA COVID-19 Uninsured Program.

Credit balances may not be resolved timely, and refunds to the HRSA COVID-19 Uninsured Program may not be identified or completed in a timely manner.

Evidence of controls addressing the risk that data within the patient accounting system may be inappropriately created or modified was not retained. Potential effects of ineffective controls related to this risk includes ineligible patients could be inappropriately identified as eligible, services could be reimbursed by HRSA for unallowable charges, or patients could be inappropriately billed for services that HRSA reimbursed under this program.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Questioned costs:

Assistance Listing No. 93.461 – \$344,580

Context:

We sampled 40 claims (totaling \$192,597 in federal expenditures) for services occurring during the award period that were billed to the HRSA COVID-19 Uninsured Program and noted three emergency and physician office claims that were inappropriately billed to HRSA (totaling \$3,548 in federal expenditures). Based on the identified errors, management performed an analysis over claims submitted to HRSA related to services with discharge dates during the award period, indicated that 251 patient accounts totaling \$338,753 related to certain outpatient claims were inappropriately billed to HRSA.

We sampled 40 claims (totaling \$192,597 in federal expenditures) for services occurring during the award period that were billed to the HRSA COVID-19 Uninsured Program for internal controls over and compliance with the determination of a patient's uninsured/self-pay status. We identified control deviations and compliance exceptions for nine patient encounters (totaling \$5,827 in federal expenditures) as follows:

- For three of nine, the self-pay flags and/or detailed notes within the patient billing and recordkeeping system were from a prior fiscal year and did not relate to the fiscal 2020 date of service.
- For two of nine, there was no self-pay flag and/or notes within the patient billing and recordkeeping system supporting the patient was uninsured/self-pay status.
- For two of the nine, the notes within the patient billing and recordkeeping system were not conclusive on the patient's uninsured/self-pay status. The patients subsequently received other insurance coverage that was backdated to the date of service paid by the HRSA COVID-19 Uninsured Program. The other insurance has not been billed and to date, the HRSA COVID-19 Uninsured Program has not been refunded.
- For two of nine, the notes within the patient billing and recordkeeping system were not conclusive on the patient's uninsured/self-pay status.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Total federal expenditures for Assistance Listing No. 93.461 totaled \$6,025,338 for the year ended December 31, 2020.

Identification as a repeat finding, if applicable:

The finding is not a repeat finding.

Recommendation:

The Clinic should implement internal controls to document its review and compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

Standard policies, procedures, and internal controls over the review for patient insurance coverage and review of credit balances should be updated to address the unique aspects of the HRSA COVID-19 Uninsured Program.

Management should retain documentation of the operation of controls responsive to risks related to the data stored in their IT systems as evidence of control activities.

Views of responsible officials:

Management agrees with this finding and is in the process of reviewing claims submitted to the HRSA COVID-19 Uninsured Program for potential payments for ineligible services and will timely resubmit any claims that require reprocessing due to overpayment. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Finding 2020-003

Identification of the federal program:

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 200.332 of the Uniform Guidance states, “All pass-through entities must:

- (d) Monitor the activities of the subrecipient as necessary to ensure that the subaward is used for authorized purposes, in compliance with Federal statutes, regulations, and the terms and conditions of the subaward; and that subaward performance goals are achieved.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Condition:

The Clinic maintains a monthly balanced scorecard to monitor that that subrecipient risk assessment are being completed timely. For 6 of 12 months during the fiscal year, there was no evidence of review and approval of the calculated metric.

The Clinic's principal investigators perform monthly/quarterly reviews of subrecipient financial and performance reports; however, documentation was not consistently completed or retained to evidence the results of the monitoring during the fiscal year.

Cause:

Evidence of review and approval was not obtained for all monthly balanced scorecards.

Established internal controls over the completion of the subaward monitoring checklist as part of the monthly/quarterly reviews were not followed during the fiscal year.

Effect or potential effect:

Subrecipients may not be monitored timely. Subaward may not be used for authorized purposes, or performance goals may not be achieved by the subrecipient.

Questioned costs:

None.

Context:

We sampled 27 monthly/quarterly subrecipient financial and performance report reviews performed throughout the fiscal year by various principal investigators and noted the subaward monitoring checklist was not included in the monthly/quarterly review materials (2 instances) or it was included in the monthly/quarterly review materials but answers to the three key questions included in the subaward monitoring checklist were not completed to evidence the results of the financial and performance review (16 instances).

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Total amount of federal monies passed through to subrecipients reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$42,217,065 for the year ended December 31, 2020. Total federal expenditures for the Research and Development Cluster are \$380,451,621 for the year ended December 31, 2020.

Identification as a repeat finding, if applicable:

The finding is a not a repeat finding.

Recommendation:

The Clinic should ensure that evidence is retained to support the operating effectiveness of established internal controls.

Views of responsible officials:

Management agrees with this finding and will ensure that proper documentation is retained to support the operating effectiveness of established internal controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Finding 2020-004

Identification of the federal program:

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Condition:

The Clinic does not have an internal control in place over the review and approval of subrecipient invoices to ensure that the payment to the subrecipient is limited to the subrecipient's immediate cash needs.

Cause:

The current review and approval process is at the time of set up of the purchase order for the total amount of the annual subaward. Invoices submitted for payment are matched to the purchase order by the purchasing system and approved for payment. However, there is no review and approval of the individual subrecipient invoice at the time of payment to the subrecipient.

Effect or potential effect:

Payments to subrecipients may not minimize the time elapsed between transfer of federal funds from the Clinic to the subrecipient and the disbursement of such funds for program purposes by the subrecipient. Payments to subrecipients may not be in accordance with the cash management requirements outlined in the subaward agreement.

Questioned costs:

None.

Context:

Total amount of federal monies passed through to subrecipients reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$42,217,065 for the year ended December 31, 2020. Total federal expenditures for the Research and Development Cluster are \$380,451,621 for the year ended December 31, 2020.

Identification as a repeat finding, if applicable:

The finding is a not a repeat finding.

Recommendation:

The Clinic should establish internal controls over the review and approval of subrecipient invoices for cash management at the time of payment to the subrecipients.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs Section (continued)

Views of responsible officials:

Management will review the subrecipient payment process to ensure appropriate internal controls over payments to subrecipients are in place.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP.
All Rights Reserved.

ey.com

Summary Schedule of Prior Audit Findings

Finding 2019–001

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

CFDA Nos.: 12.300, 12.RDC, 93.173, 93.242, 93.273, 93.286, 93.301, 93.310, 93.350, 93.393, 93.394, 93.395, 93.397, 93.399, 93.837, 93.846, 93.847, 93.853, 93.859, 93.865, 93.866, 93.RDC

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Mayo Clinic's (the Clinic) internal control over Information System (IS) Programmers internal service charges does not require that the initial request for services always be completed or approved by the Principal Investigator (PI) or appropriate individual with authority on the grant. In addition, the specific grant activity number to be charged is not always documented during the intake process when the initial request for services is made.

Recommendation:

The Clinic should update its policies and procedures to include an internal control over the approval of IS Programmer service charges.

Status

Corrective action was taken as planned and full implementation of the corrective action plan began in fiscal year 2021.

Contact Person

Lance A. Guth, Section Head IT – Administrative, Research & Education Applications

Corrective Action Plan

Finding 2020-001

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 93.173, 93.273, 93.286, 93.307, 93.310, 93.350, 93.353, 93.393, 93.394, 93.395, 93.397, 93.398, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Periods: Various

Corrective Action Planned

Information Technology (IT) implemented corrective actions as planned following completion of the 2019 audit. Those corrective actions require that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. IT will supplement these corrective actions with additional communications about expectations, and retrospective confirmations of ongoing work to ensure appropriate documentation exists for both new and ongoing work.

The intake process for the Biomedical Imaging Resource (BIR) Core will be reviewed and enhanced as needed to ensure appropriate documentation supporting the request for services is captured and retained.

Person Responsible for Corrective Action

Lance A. Guth, Section Head IT – Administrative, Research & Education Applications

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Anticipated Completion Date

September 30, 2022

Finding 2020-002

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: February 4, 2020 through December 31, 2020

Corrective Action Planned

Management is in the process of reviewing claims submitted to the HRSA COVID-19 Uninsured Program for potential payments for ineligible services and will timely resubmit any claims that require

reprocessing due to overpayment. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Person Responsible for Corrective Action

Sharon M. Kelley, Chair – Revenue Cycle
Michelle Densley, Director – Revenue Compliance

Anticipated Completion Date

May 31, 2022

Finding 2020-003

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Corrective Action Planned

Monitoring over subrecipient risk assessments will be enhanced to ensure timely review and approval occurs.

Routine reviews of subrecipient performance and progress will be reviewed and enhanced to ensure documentation supporting the results of the monitoring is consistently completed and retained.

Person Responsible for Corrective Action

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Anticipated Completion Date

September 30, 2022

Finding 2020-004

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Corrective Action Planned

Internal controls over payments to subrecipients will be reviewed and enhanced or established as needed to ensure the appropriateness of such payments.

Person Responsible for Corrective Action

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Anticipated Completion Date

December 31, 2022